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Abstract
BACKGROUND:
Breast cancer is the most commonly diagnosed cancer and second leading cancer death cause among
females in the U.S.A. About 1 in 8 women in U.S will develop invasive breast cancer over the course of her
lifetime. In 2013, 234,580 new invasive breast cancer cases are expected to occur in women within the US
and approximately 64,640 non-invasive carcinomas in situ were diagnosed in 2013, most of which were
ductal carcinoma in situ (DCIS). Along with technological advances, a wide variety of candidate
biomarkers have been proposed for cancer diagnosis and prognosis, including DNA content and noncoding RNA. Current techniques for detecting DNA content abnormalities in formalin-fixed, paraffinembedded (FFPE) tissue samples by flow cytometric analysis have used cells recovered from ≥50µm whole
tissue sections. Here, in our first study, a novel core punch sampling method was investigated for assessing
DNA content abnormalities and intratumoral heterogeneity in FFPE specimens. Secondly, long non-coding
RNAs (lncRNAs) has been examined. LncRNA participates in a broad spectrum of biological activities by
diverse mechanisms and its dysregulation is associated with tumorgenesis. Some lncRNAs may function as
oncogenes (O) and others as tumor suppressor genes (TSG). To date, lncRNA has been investigated
primarily by qRT-PCR and RNA sequencing. This study has examined the relationship of lncRNA
expression patterns to breast tumor pathology by chromogenic in situ hybridization (CISH).
METHODS:
Firstly, FFPE breast carcinoma specimens were selectively targeted using 1.0 mm diameter punch needles.
Extracted cores were assayed by flow cytometry using a modified-Headley method. Secondly, the lncRNA
expression levels of 6 lncRNAs: HOTAIR, H19, KCNQ1OT1, MEG3, MALAT11 and Zfas1, was
examined by RNAscope® CISH using FFPE breast tissue microarrays (TMAs) comprising normal adjacent
epithelia (NA), DCIS, and invasive carcinoma (IC) from 46 patients. LncRNA associate polycomb
complex protein EZH2 was evaluated by immunohistochemistry (IHC). LncRNA data was also compared
to standard breast tumor data including ER, PR, Her2 and Ki67 IHC. SYSTAT version 11 statistical
package was used to perform for all the tests.
RESULTS:
Following optimization experiments of the core punch flow cytometric approach, DNA index and percent
S-phase fraction intratumoral heterogeneities were detected in 10/23 (44%) and 11/23 (47%) specimens
respectively. The lncRNA CISH study utilized a TMA that contained 36 spots of NA breast tissues, 34
DCIS spots and 43 IC spots. HOTAIR CISH staining was significantly stronger in IC than DCIS (p<0.001)
and NA spots (p<0.001). In DCIS, HOTAIR was correlated with Her2 (p=0.03) IHC. And in IC, the data
suggest HOTAIR is a marker for high histological grade (p=0.026). H19 was rarely expressed in normal
adjacent epithelial or tumor cells but was strongly expressed especially in inter-lobular stromal cells around
invasive growths (p<0.001). H19 correlated with Ki67 IHC expression in DCIS, (p=0.047). KCNQ1OT1
expressed stronger in IC and DCIS than in NA (p<0.001), and was associated with Her2 (p= 0.032) in IC.
No significant expressional difference was found in MEG3. MALAT1 stained strong universally and Zfas1
was very faint in all samples; as such neither of these was analyzed statistically. Polycomb protein EZH2
expressed differently among tissues but did not correlate with lncRNA levels.
CONCLUSION:
Core-punching is an effective alternative to whole specimen sectioning and shows that macro-level
genomic heterogeneity is common even within a single FFPE block. The interrelationship of DNA content
heterogeneity to other forms of heterogeneity requires further study. RNAscope CISH supports bright-field
microscopy investigations of lncRNA expression in FFPE tissue specimens. HOTAIR, H19 and
KCNQ1OT1 may be potential breast cancer biomarkers, both HOTAIR and H19 may be a marker for DCIS
at increased risk of progression to invasive cancer. HOTAIR, in particular, may be a predictor for invasive
cancer grade.
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Comprehensive Literature Review
Introduction
Breast cancer is the most commonly diagnosed cancer and second leading cause of cancer death
among females in the U.S (CDC website). In 2013, 234,580 new invasive breast cancer cases are
estimated to occur in women in U.S, whereas 2,240 cases are expected in men (Siegel,
Naishadham et al. 2013). In addition to invasive breast cancer, around 64,640 new cases of noninvasive carcinoma in situ in women breast, most of which are ductal carcinoma in situ (DCIS),
are predicted to be newly diagnosed in 2013 (Siegel, Naishadham et al. 2013). About 14% female
cancer deaths in 2013 are estimated to result from breast cancer (Siegel, Naishadham et al. 2013).
With the advancement of classification systems, screening techniques and therapeutics, more and
more females have been diagnosed with breast cancer at younger ages and have received better
treatment. Breast cancer caused female deaths have decreased steadily since 1990, with a
dramatic decrease in women aged 20-69 years old (Lacey, Devesa et al. 2002; Bray, McCarron et
al. 2004). Rather than invasive breast carcinoma, which is able to metastasize to regional lymph
nodes or distant sites, DCIS is confined within the basement membrane of ducts and lobules and
often co-exists with invasive cancer cells; it can eventually develop to invasive cancer. The
treatment for DCIS has become a widespread medical issue because of malignant uncertainty
(Ernster and Barclay 1997; Duffy, Agbaje et al. 2005; Virnig, Tuttle et al. 2010) and most
patients get treated with surgery, breast irradiation and endocrine therapy (Baxter, Virnig et al.
2004), however, about 70% of DCIS have been found not to have a devastating impact on a
patient’s life (Page, Dupont et al. 1982; Eusebi, Foschini et al. 1989; Eusebi, Feudale et al. 1994).
Chromosomal instability (CIN), resulting from elevated rate of chromosome missegregation
during mitosis, is a hallmark of cancer. DNA ploidy changes are one consequence of CIN and
typically result in abnormal DNA content (Fridlyand, Snijders et al. 2006). Sporadic tumors likely
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develop through processes involving chronic sub-clonal diversification and accumulation of
genomic aberrations resulting in intratumoral heterogeneity, which is being unveiled by largescale massively parallel sequencing and paving the path for personalized medicine(Campbell,
Pleasance et al. 2008; Campbell, Yachida et al. 2010; Michor and Polyak 2010).
Long non-coding RNA (lncRNA), transcribed RNA molecules greater than 200 nucleotides in
length, has been demonstrated to be involved in multiple biological activities including
epigenetics regulation, transcriptional regulation, interaction with small non-coding RNA, posttranscriptional regulation, nuclear compartment formation and cell cycle control (Gupta, Shah et
al. 2010; Hung, Wang et al. 2011; Tsuiji, Yoshimoto et al. 2011; Schor, Lleres et al. 2012; Han,
Liu et al. 2013; Luo, Li et al. 2013; Tripathi, Shen et al. 2013). Both DNA content abnormalities
(Pinto, Monteiro et al. 2005; Bremmer, Brakenhoff et al. 2011) and lncRNAs (Dhanasekaran,
Barrette et al. 2001; He, Bao et al. 2014; Zhao, Guo et al. 2014) have already been suggested as
biomarkers in some cancer types, but this has not yet been investigated in DCIS. Understanding
the potential role of CIN, intratumor heterogeneity and lncRNAs in breast tumor pathology would
be valuable to science and medicine by creating better diagnostic methods, screening options and
treatments.
Breast cancer symptoms
Early breast cancer doesn’t cause any significant symptoms, so regular breast test is required.
Although patients are not able to notice a lump on breast, which is a very typical symptom for a
breast tumor, people can still pay attention to subtle changes to the body to get some clues for
early disease. These signs include subtle changes in breast size and shape, some morphological or
color changes in skin, for example, dimpling, swelling or becoming red. As a tumor grows,
apparent symptoms can be seen, including a breast lump or lump in the armpit that are hard and
have uneven edges, more visible changes in breast size, shape, or a recent nipple change, as
2

example, nipple inversion, nipple ulceration, retraction, bloody discharge as well as peeling,
However, more than 80% breast cancer case are detected by breast lump (Therapy 2003). When
cancer advances, there are a more symptoms that can be noticed by both patients and clinicians.
Bone pain, breast discomfort, skin ulcers, swelling of one arm and weight loss are important
features at that stage. According to different presentations of breast cancer in different stages, a
complete test that helps doctors determines the exact stage that is necessary. Physical exams
include breasts, armpits, and the neck and chest area and a variety of methods are combined. For
instance, magnetic resonance imaging (MRI) scan can provide clinicians with better identification
of a breast lump or an abnormal mammogram changes, ultrasound can be utilized to show
whether the lump is solid or not, and biopsies help pathologists to stage or come up with a
treatment decision. Computerized tomography (CT) scans can contribute to analyzing the tumor
spread. To test a very subtle change in breast contour, the test must contain one assessment of the
breast with patients upright with arms raised. If some symptoms like contour change, skin
tethering, dilated veins, ulceration, or Paget’s disease are found then clinicians become more
concerned about the patient. Paget’s disease, whose symptoms include eczematoid skin, is
diagnosed in almost a quarter of the female patients (NCI 2005). Additionally, tests on axillae and
supraclavicular fossae areas and additional abdominal and neurologic examination should be
included to make a complete evaluation because there might be some symptoms indicating
metastasis occurring in such places. These symptoms include breathing difficulties, bone pain,
symptoms of hypercalcemia, abdominal distention, jaundice, localizing neurologic signs, and
altered cognitive function.
Though a lump is an indicator for breast tumor, it is quite indiscernible and hard to detect
inflammatory breast cancer, which can pose a substantial diagnostic challenge. For diagnostic
purposes, people who may have this type of cancer should pay attention to symptoms that
3

resemble a breast inflammation as well as itching, pain, swelling, nipple inversion, warmth and
redness throughout the breast. Moreover, peau d'orange, which is an orange-peel texture on skin
could be another sign. Occasionally localized breast cancer cells metastasize to other locations
through the body including bone, brain, liver and lung. Unexplained weight loss and fever
sometimes presage occult breast cancer and pains in the bones or joints could also manifest
metastatic breast cancer, however all these symptoms are non-specific, meaning they could also
be indications of other diseases.
Breast cancer histology features and classification
The accurate diagnosis and pathological assessment are key steps undertaken by pathologists,
who need to differentiate benign breast tissues from early and established breast cancers. Then, an
evaluation of pathological features and suggestions for treatment should be provided by
pathologists (Russo and Russo 1992). Carcinomas are most common malignant tumor types for
breast tissues and can be divided into two groups: carcinoma in situ and invasive carcinoma. And
since most breast carcinomas are derived from epithelium of ducts or lobules, we also define
them as mammary ductal carcinoma and lobular carcinoma. By histopathological evaluation, the
three most frequent carcinoma types are invasive ductal carcinoma (55%), DCIS (13%) and
invasive lobular carcinoma (5%) comprising about approximately 75% of all incidence (Eheman,
Shaw et al. 2009). Invasive carcinoma usually presents with a large breast mass and sometimes
with nipple discharges or breast pain. When observed by microscopy, invasive carcinoma is more
fixed asymmetrically and not well circumscribed. However, nearly all triple negative tumors
present solid architectures without forming tubules and have a large amount of tumor cells with
little stromal area between these cells, demonstrating very detailed morphological difference. In
addition, above half of basal-like tumors exhibit a pushing border and have stromal lymphocytic
infiltration at the edge of tumor to some extent (Livasy, Karaca et al. 2006). DCIS, with the
exception of neoplastic epithelial proliferation within the ducts basement membranes shares some
4

symptoms with invasive cancer and surprisingly, many similarities between DCIS cells and
invasive carcinoma cells are found, on both cellular and molecular levels (Ma, Salunga et al. 2003;
Hannemann, Velds et al. 2006; Kuerer, Albarracin et al. 2009).
Immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) are valuable tools for
histological assessment to identify estrogen receptor (ER), progesterone receptor (PR) and human
epidermal growth factor receptor 2 (Her2) expression status. Sentinel lymph node biopsy is
another method to aid histological assess, especially for metastatic status (Veronesi, Paganelli et
al. 1997).The nearest single lymph node to primary breast tumor is removed and examined in
detail to see if there are some tiny clusters of metastatic cells. If no tumor cells are found,
pathologists can predict a very low chance to get metastatic cells in axillary lymph nodes, and
therefore, full lymph node excision is not necessary. The classification of the invasive breast
cancer aims to classify breast cancers into various categories according to different criteria in
order to primarily help select the best therapeutics and provide a better prognosis. In 2003, the
World Health Organization recommended a comprehensive breast cancer classification system
including both non-malignant and malignant tumors to help clinicians to better identify tumor
types and specific treatments (Tavassoli, Devilee et al. 2003). Histopathology, tumor grade,
tumor stage and receptor expression status are most commonly used criteria for classification.
Tumor grade relies on the similarity and differences between cancer cells and normal cells and
thus divides tumor into three major groups: low grade (well-differentiated), intermediate grade
(moderately differentiated) and high grade (poorly differentiated). Usually well-differentiated
tumor has a better prognosis due to its similar appearance as normal cells. The overall grade is
assessed by the Nottingham system (Genestie, Zafrani et al. 1998; Simpson, Gray et al. 2000),
which generates the overall scores by totalizing scores for nuclear features, tubule formation and
mitotic activity, each of which is scored from 1 to 3 points. Nuclear feature is used to assess how
5

much variation tumor cell nuclei have compared with normal breast cells nuclei, while tubule
formation is a parameter that evaluates how much tumor has the normal structure of ducts.
Uncontrolled cell division is one of the hallmarks of cancer, so mitotic count is a parameter to
assess how many dividing cells can be seen in 10x microscope fields. The sum of three points
can lead to a conclusion: 3-5 points means grade 1 tumor which is the best among the three, 6-7
represents grade 2 tumor and 8-9 points is grade 3 tumor. Tumor stage is a criterion which
determines how severe the cancer is and often come along with estrogen/ progesterone receptor
expression levels, Her2 status and menopausal status for a diagnostic decision. At present, the
tumor, nodes and metastases (TNM) staging system is the most widely used in world. Tumor
value is based on the primary cancer and lymph node value depends on cell number, size in
regional lymph nodes, and metastases value refers to the information of metastatic cancer. Both
grade and staging units contribute to The Nottingham Prognostic Index (NPI) (Galea, Blamey et
al. 1992). NPI= (0.2 x tumor size (cm)) + tumor grade + stage, is an equation to stratify patients
into different prognostic group, due to which, favorable prognosis has scores below 3.4 and
medium gets scores between 3.41 to 5.4. However, poor prognosis has a score greater than 5.41
(Galea, Blamey et al. 1992).
IHC and FISH tests for ER, PR, and Her2 are the most common methods to help classify breast
cancers and of great importance as a guide for therapeutics. Based on different receptor
expression, most breast cancers are categorized to five groups including luminal A/B, Her2+,
triple-negative Claudin-low and normal basal-like (Perou, Sorlie et al. 2000). Estrogen receptor
positive (ER+) cancer cells can be treated with tamoxifen (Jordan and Koerner 1975) or
aromatase inhibitors (AIs) (Smith and Dowsett 2003)to reduce estrogen effect or decrease ER
expression level because these cells need estrogen to grow, while monoclonal antibody
trastuzumab can precisely target Her2 positive cancer cells and thus highly improve breast cancer
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therapeutics combining with traditional chemotherapy (Romond, Perez et al. 2005). In terms of
DCIS, the current pre-mammography classification is predominately relied on microscopic
features: comedo, solid, papillary, micropapillary and cribriform (Allred 2010). The grading
system refers to the degree DCIS cells resemble normal cells, the level DCIS cells differentiate,
conveying criteria from existing invasive breast cancer histology grading pattern since we know a
positive relationship between tumor cell differentiation and cancer aggressiveness (Elston and
Ellis 1993).
Genetics
BRCA1 and BRCA2 are most important hereditary genes in breast cancer genetics. More than
200 germline mutations in BRCA1 and over 100 mutations in BRCA2 shows clear associations
with breast cancer susceptibility and have been registered in the Breast Cancer Information Core
Database (Szabo, Masiello et al. 2000). Mutations of BRCA1 and BRCA2 have been reported to
account for almost 20-25% familial breast cancer cases but less than 10% of overall breast
cancers. The majority of known mutations in BRCA1 and BRCA2 are predicted to result in
premature translation termination (Easton 1999). BRCA1 encodes a 220kD nuclear protein and
its molecular functions are to control cell cycle (i.e., functional BRCA1 missing will cause cell
cycle arrest) and responses to DNA damage (Gowen, Avrutskaya et al. 1998; Scully and
Livingston 2000). In the meantime, BRCA1 is also a component of the RAD51-MRE11-p95
complex that works for DNA repair system (Scully, Chen et al. 1997). BRCA2 encodes a bigger
protein which also involves in DNA double-strand break repair and maintains chromosome
integrity (Chen, Silver et al. 1999). Approximately 15-20% women have been found with BRCA1
mutation if someone had breast cancer in their family history and the number is 60-80% when
their families showed both breast and ovarian cancer (Couch, DeShano et al. 1997). These
mutations carriers have a chance of 60-80% to get breast cancer through their lifetime, with a
median diagnosed age of 20 years as compared to those women who do not have BRCA1
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mutations (Easton, Narod et al. 1994; Struewing, Tarone et al. 1996). Females who carry BRCA2
mutation will also have 60-80% chance to get cancer eventually, while men with BRCA2
mutations will surprisingly develop a 6% lifetime breast cancer risk. It has been found those
BRCA associated cancers appears in patients’ at younger ages and are more dangerous. BRCA1
mutations have been shown to associate with triple negative breast cancer (TNBC), while
mutations in BRCA2 are more likely to be found in post-menopausal breast cancer.
Scientists have also found several germline genetic mutations that contribute to breast cancer risk
by analyzing familial data, including STK11/LKB1, phosphatase and tensin homolog (PTEN),
androgen receptor (AR) and p53 (Malkin, Li et al. 1990; Wooster, Mangion et al. 1992; Liaw,
Marsh et al. 1997; Boardman, Thibodeau et al. 1998). However, all these genetic factors
mentioned above are rarely found across the population so that they can only account for a very
small portion of heritability of human breast cancer. As techniques develop, the secrets of breast
cancer genetic world are rapidly getting dissected. With comparative genomic hybridization
(CGH), patterns of chromosome gain and loss have characterized breast cancer of different grades
(Roylance, Gorman et al. 1999). Losses of 11q, 8p, 13q, gains on 1q, 8q, 17q are high grade
invasive breast tumor signatures whereas low grade cancers commonly show gains on 1q, 16p, 8q
and loses of 16q (Buerger, Otterbach et al. 1999; Roylance, Gorman et al. 1999). Noticeably,
DCIS shows high similarities to genetic abnormalities found in invasive cancers (Buerger,
Otterbach et al. 1999). Advanced high-throughput sequencing have identified many susceptible
loci in candidate genes, single nucleotide polymorphisms (SNP) and copy number variations
(CNV) in somatic cells that are highly associated with breast cancer. MAP3K1, AKT2 and
CDKN1B are newly found genes that contribute to breast cancer susceptibility (Stephens, Tarpey
et al. 2012). Together with meta-analysis, results from different genome–wide association studies
can by synthesized to better identify some widely-accepted loci in different race, e.g., 6q14 and
20q11 (Siddiq, Couch et al. 2012).
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Screening
Screening for breast cancer is for apparent healthy women to get an early diagnosis, which will
largely improve the final outcomes. Several tests have been utilized including self and clinical
breast exams, mammography, genetic screening, MRI and ultrasound. In 2003, a review
demonstrated that breast cancer examination did not associate with lower death rates and so did
not recommend self or clinical exams (Kosters and Gotzsche 2003). Mammography utilizes a
specialized X-ray machine which emits a small amount of ionizing radiation to get the X-ray
image, which will be on plain digital mammography or photographic film on a computer screen,
interpreted by radiologists and now it becomes a very common breast cancer screening test
among women ages 40 to 74 because of its quickness and wide availability (Mandelblatt, Cronin
et al. 2009). Overall, mammography saves a small number of lives and is more effective in older
aged women but it has no benefits for predicting the outcome of that cancer. Recommendations
about what time and what frequency it is best to undergo mammography screening vary across
the world. Although mammography offers a small, but statistically significant benefit, it also
creates some criticism because many patients overestimate the effect that mammography provides
and this often results in heavy psychological and financial burden. MRI is another tool in
screening breast cancer with a very high negative predictive value and it can also diagnose benign
proliferative changes, fibroadenomas and some other benign findings. In terms of shortcomings,
it is much less specific than mammography, more expensive and less available in some
developing countries. The third screening method is genetic test, which can only reveal a
susceptibility to develop cancer rather than detect cancer. Due to significant role of BRCA
mutation in promoting breast cancer, US government published a clinical practice guideline to
recommend women for BRCA mutation test (Nelson, Huffman et al. 2005). About 2% of
American women have family histories have been found with an increased risk of having a
medically significant BRCA mutation after genetic test (Nelson, Huffman et al. 2005).
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Therapeutics
The mainstay of breast cancer treatment is surgery if the tumor is localized and the following
treatments are chemotherapy, radiotherapy and hormonal therapy. There is no general treatment
for all kinds of breast cancer so it is very important to identify what specific molecular subtype
the patient has beforehand. TNBC has been given first priority currently by clinicians around the
world because it has the worst prognosis among all breast cancer subtypes. Multiple clinical trials
have been tried on TNBC patients and it has already been found that several chemotherapeutic
drugs and biological agents are very promising. DNA-damaging compounds like platinate agents
should be useful because platinum compounds function in developing a covalent bifunctional
cross-linked adducts, which blocks DNA double-strand break caused by replication forks
(Helleday, Petermann et al. 2008; Bosch, Eroles et al. 2010). Epidermal growth factor receptor
(EGFR) is another therapeutic target because it is expressed in 45-70% TNBC cases, but target
antibody or drugs including Cetuximab still await assessment (O'Shaughnessy 2007).
Angiogenesis is critical for tumor growth so drugs that specifically target neoangiogenesis is
another treatment option. Bevacizumab was approved by FDA to treat metastatic Her2-negative
breast cancer in combination with paclitaxel due to results of the phase III clinical trial E2100
(Miller, Wang et al. 2007). Another clinical trial that tested Bevacizumab detected a statistically
significant difference in progression-free survival between women taking bevacizumab and
docetaxel (Miles D 2008) .Last but not at least, PARP inhibitors are compounds that work to
inhibit already defective DNA repair, which could be potentially used.
Lumina A type, which is a low grade breast cancer that is ER-positive and Her2-negative, has the
best prognosis among all the subgroups. It seems there is no standard treatment for luminal A and
it depends on an individual’s traits, tumor size, histological grade and lymph node conditions.
Luminal B type is a higher grade breast cancer that is ER-positive and Her2-negative, and a
potential target is insulin-like growth factor signaling, to which clinicians adopt IGF-1R antibody
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or small molecule inhibitors to block this pathway (Atzori, Traina et al. 2009). In addition,
endocrine therapy plus PI3K inhibitors dramatically improve treatment efficiency for luminal B
breast cancer, while highly specific PI3K inhibitors are in development to reduce unexpected side
effect (Creighton, Fu et al. 2010). Patients that are Her2-positive are likely to have poorly
differentiated tumors with a relatively high level proliferation rate and associated with increasing
risk of recurrence and death. Trastuzumab, which is an engineered antibody with a high affinity
for Her2 extracellular transmembrane protein, has had a major impact in the treatment of Her2positive metastatic breast cancer with cytotoxic agents (Hortobagyi 2005). In terms of treating
DCIS, there are three major options: 1) Breast-conserving surgery and radiation therapy with or
without tamoxifen; 2) Total mastectomy with or without tamoxifen; 3) Breast-conserving surgery
without radiation therapy, but the results are pending because of poor accuracy.
Biomarkers for breast cancer
Cancer biomarker refers to any molecule secreted by tumors or responses of body that are
indicative of the presence of the cancer. Genetics, epigenetics, proteomics, metabolomics,
glycomic as well as imaging biomarkers can be applied to cancer diagnosis, prognosis and other
aspects. For breast cancer, although classical histopathological features play important roles in
diagnosis, prognosis and treatments, in the era of big data, several novel biomarkers have been
proposed and validated to improve clinical prediction and have become clinical routine tests for
breast cancer. Genetic alternations in either BRCA1 or BRCA2 seem to account for about 20-25%
of familial cancer incidences, which consists approximately 5-10% all breast cancer cases (Easton
1999). Particularly the 3 major mutations are: 185delAG, 5382insC in BRCA1 and 6174delT in
BRCA2. BRCA1 mutations carrier have a dramatically lower short-term and long-term survival
rates and a significantly lower progression-free survival rate, while BRCA2 mutation does affect
neither short-term nor long-term survival rate but associates with an increased risk of pancreatic
cancer (Lee, Park et al. 2010). Estrogen receptor (ER) is the most important biomarker in breast
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cancer and its status directs the therapy option to endocrine therapies because all the ER-positive
tumors use steroid hormone estradiol as their primary growth stimulus. Progesterone receptor (PR)
expression is dependent on the present of ER and there is <1% of breast cancer cases express only
PR but not ER. Considering breast cancer early detection, serum tumor marker like
carcinoembryonic antigen (CA) has not been demonstrated to be sensitive for early detection
(Hayes 1996), while mammaglobin and maspin seems to be promising for that purpose (Maass,
Nagasaki et al. 2002; O'Brien, Maguire et al. 2002). From the point of view of diagnosis,
cytologic examinations for nipple duct fluid has used for decades and one study which applied
protein chip method to analyze nipple fluid revealed some potential biomarkers, e.g., a 15940-Da
protein was found with a 80% sensitivity and 100% specificity (King, Chew et al. 1983; Sauter,
Zhu et al. 2002). Immunohistochemical staining for other glycoproteins such as B72.3, alactalbumin and milk fat globule, showed their potential in identifying metastasis in breast cancer
(Lee, DeLellis et al. 1984; Hilborne, Cheng et al. 1986). Furthermore, the functions of DNA
ploidy and S-phase fraction in predicting prognosis have been put forward a long time ago but
vary greatly among studies. Currently, neither the American Society of Clinical Oncologists (Bast,
Ravdin et al. 2001) nor the College of American Pathologists (Hammond, Fitzgibbons et al. 2000)
recommend ploidy status and S-phase fraction as standalone prognostic marker. Ki-67 staining is
a common method to reveal cell proliferation and it is more consistent than ploidy and S-phase
fraction measurement alone. The epidermal growth factor receptor (EGFR) are overexpressed
widely among breast cancers and famous Her2/neu is a member of EGFR and amplified in 10-34%
invasive breast cancer (Ross and Fletcher 1999). Both molecular techniques and morphology
techniques are applied to measure Her2/neu status clinically. Immunohistochemistry staining,
fluorescent in situ hybridization, southern blot, RT-PCR, and enzyme-linked immunosorbent
assay (ELISA) are common methods to test Her2/neu but none of these methods is perfect (Hillig,
Thode et al. 2012). Additionally, Her2/neu is also an important marker in monitoring treatment
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for trastuzumab (Esteva, Cheli et al. 2005). Besides EGFR, other growth factor like transforming
growth factor a (TGF-α), TGF-β, insulin-like growth factor (IGF) - I and –II, platelet-derived
growth factor (PDGF), fibroblast growth factor (FGF) and vascular endothelial growth factor
(VEFG) are all associated with breast cancer prognosis to some extent (Bonneterre, Peyrat et al.
1990; Castellani, Visscher et al. 1994; Yiangou, Gomm et al. 1997; Dumont and Arteaga 2000;
Shao, Nguyen et al. 2000; Linderholm, Lindahl et al. 2001).
Genomic instability and flow cytometry
Genomic instability indicates an increased rate of genomic aberrations of a cellular lineage and it
is believed to be necessary for carcinogenesis. Those alternations include nucleic acid sequence
changes, chromosomal rearrangements and aneuploidy. Genomic instability was first
characterized in colorectal cancers in two groups: microsatellite instability is due to defects in
DNA mismatch repair, causing mutations in gene sequences at simple repeats; the other type,
which is much more common, is called chromosome instability (CIN) (Lengauer, Kinzler et al.
1997; Lengauer, Kinzler et al. 1998). The underlying mechanism is not well known but it likely
results from elevated rate of chromosome missegregation during mitosis. Telomere dysfunction
has also been presented as another mechanism for genomic instability (Artandi and DePinho
2000). Traditionally, many breast genomic alternations were described as gains and losses,
including DNA amplifications at 11q13, 17q12, 8p12 and 8q24 from cytogenetic analyses, FISH
and CGH (Gray, Collins et al. 1994). The advent of array CGH improves the analysis and
contributes to identify copy number variation, single nucleotide polymorphism at a highresolution genomic profile level (Loo, Grove et al. 2004; Bergamaschi, Kim et al. 2006; Staaf,
Jonsson et al. 2011; Krepischi, Achatz et al. 2012). Aneuploidy, a type of chromosomal
abnormality, represented by numerical changes in whole chromosomes, is usually indicated by
abnormal DNA content. Aneuploidy consistently occurs in all cancers but is less well studied
than structural chromosome alternations. Since genes and pathways which are deregulated by
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aneuploidy are still unknown, it is possible that these genomic alternations have a more complex
effect on carcinogenesis. In aneuploid chromosomes, candidate genes are more difficult to
identify due to big genomic regions and potential gene-gene interactions (Gordon, Resio et al.
2012). Flow cytometric measurement of nuclear DNA content renders reliable information about
DNA ploidy and estimation of tumor cell genetic instability. DNA index, which is the ratio of
tumor sample / standard DNA fluorescence channel measured by flow cytometer, is frequently
applied to show DNA content difference among tumors, has become a prognostic and diagnostic
marker in cancers (Pradhan, Abeler et al. 2012; Giaretti, Monteghirfo et al. 2013). Initially, dyes
that binds double strand DNA must be added into single cells suspension. The scheme is that the
stained cells have incorporated an amount of dye proportional to the amount of DNA measured in
the flow cytometer and the emitted fluorescent signal yields an electronic pulse that is
proportional to the total fluorescence emission from the cell. Considering the scatter provided by
the cytometer, forward scatter is designed to measure cell size, while side scatter is used to
indicate cellular complexity and granularity. This combination of scattered and fluorescent light
is picked up by the detectors, and, by analyzing fluctuations in brightness at each detector, it is
then possible to collect various types of information about the physical and chemical structure of
each individual particle. The fluid rate should not be too high in order to yield a good signal of
discrimination between singlets or doublets and the final collected cell number should be more
than 5000. As DNA content could be not shown directly by flow data and thus reference cells for
example human red blood cells, chicken red blood cells or some external control, should be
included every time to help identify the positions of normal diploid DNA.
Long non-coding RNA
Long non-coding RNA (lncRNA) is a transcribed non-coding RNA molecule greater than 200
nucleotides in length. LncRNA is an emerging focus in biomedical research. Studies have now
demonstrated or implicated lncRNAs as important participants in a wide spectrum of processes in
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the normal or abnormal development in organisms even though it was termed as “junk” or
“transcriptional noise” several decades ago. Scientists had found some lower order animals have
much larger genomes than that of higher animals including humans. The C-value paradox: why
the amount of DNA in the haploid genome does not correspond with organism size or
developmental complexity, was firstly solved by the discovery of non-protein-coding transcripts
(Thomas 1971). In 1970s, with the advancement of biotechnique, e.g., DNA-RNA hybridization,
it has been suggested that human would not have >20,000 genes and the rest space of human
genome were mostly possessed by noncoding genes, which was called “junk DNA” at that time
(Comings 1972). However, massively distributed non-coding genes also brought scientists
another hypothesis: junk DNA may be useful, and a number of early hypothesized functions were
also proposed, including genome integrity, gene regulation, mRNA processing, etc. (Britten and
Davidson 1971; John and Miklos 1979; Lewin 1982). More transcripts that do not account for
coding sequences have been found, e.g., tRNAs, rRNAs, snoRNAs in 1970s and 1980s but
scientists could not elaborate non-coding genes until late 1990s, with the invention of wholegenome sequencing. Now, it has been estimated that approximately 70-90% of human genome
will be transcribed at some points during development in spite of low inter-species conservations
and some low expression transcripts (Wang, Zhang et al. 2004; Djebali, Davis et al. 2012; Mercer,
Gerhardt et al. 2012); conserved lncRNAs number only a few thousand (Ponjavic, Ponting et al.
2007). It might be because lncRNAs don't require very much nucleotide sequence conservation to
maintain their functionality, as compared with protein coding genes which are under strong
selection restraints to maintain codons or open reading frames (Ponting, Oliver et al. 2009).
However, one recent paper calculated and found a higher sequence conservation in lncRNA
promoters than that in protein coding genes promoters in mice, indicating although lncRNA
sequences might not be highly conserved, the level of their transcription is (Carninci, Kasukawa
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et al. 2005). To classify a large magnitude of lncRNAs, one of useful manners is to sort according
to their genomic locations, by which we can categorize them into five distinct groups:
1) Stand-alone lncRNAs, which are located in small or large interspace of protein-coding genes
(Cabili, Trapnell et al. 2011).
2) Pseudogenes, which are extra genes copies that have lost their protein-coding potential. Only
a small portion of pseudogenes are transcribed and also have acquired function during
resurrection (Bekpen, Marques-Bonet et al. 2009).
3) Natural antisense transcripts (NAT), which are derived from the opposite strand to sense
DNA strand. About 70% of sense transcripts have been found with some antisense
counterparts (He, Vogelstein et al. 2008). Sense-antisense pairs can be formed by two coding
mRNAs, coding/non-coding RNAs or dual non-coding RNAs.
4) Intronic non-coding RNAs, which are harbored within introns.
5) Transcription elements associated transcripts, which are non-coding RNAs produced or
processed within or near the sequence of promoter, enhancer or transcription start site in both
sense and antisense direction.
From various studies in lncRNAs in last decade, it is now obvious that lncRNAs contribute to a
variety of developmental processes and diseases, but mostly the molecular mechanism details that
lncRNAs employ have not been demonstrated or verified. Based on a few relatively well-studied
examples, we can still distill the functions into several types though many lncRNAs may be
implicated in various mechanisms. One of the major themes is about the role of lncRNAs in
epigenetics. LncRNAs of this group can both interact with chromatin in cis, regulating genes
nearby; or in trans, functioning towards distant genes. Chromatin-modifying elements such as
polycomb repressive complex 2 (PRC2) recently have been found to interact with multiple
lncRNAs recently (Khalil, Guttman et al. 2009; Tsai, Manor et al. 2010; Aguilo, Zhou et al. 2011;
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Guil, Soler et al. 2012). HOTAIR, an lncRNA transcribed from HOXC cluster, is one of the beststudied lncRNAs that dictates methylation of H3 on K27 and thus repress genes expression by
interacting with PCR2 (Rinn, Kertesz et al. 2007). Not only PRC2, HOTAIR was also found to
bind a second complex containing CoREST, REST and LSD1 in a different location to
demethylation H3 on K4 and thereby inhibit target gene activation (Tsai, Manor et al. 2010).
Similarly, lncRNAs KCNQ1OT1 and Air recruit chromatin-modifying complex to silence
multiple gene in their imprinted gene domains, respectively. KCNQ1OT1 interacts with PRC2
and G9a, both of which are histone methlytransferases, in cis to repress gene expression, while
Air only brings G9a to its target promoter to form a repressive domain (Nagano, Mitchell et al.
2008; Mohammad, Mondal et al. 2009).
X chromosome inactivation (XCI) inactivates one X in female cells to equalize gene expression
between males and females. The XCI process is largely controlled by a lncRNAs enriched cluster
known as the X-inactivation center. Xist, a 17kb transcript, “coats” X chromosome and recruit
silencing complex including PRC2, resulting in a chromosome-wide gene inhibition (Zhao, Sun
et al. 2008).
Another major function that lncRNAs have is to regulate transcription directly. LncRNA can act
as a molecular decoy, by which lncRNA binds to specific transcription factor or other regulatory
factors, which is necessary for target gene transcription initiation. PANDA, a p53 dependent
lncRNA in cell cycle, works as a decoy to sequester transcription factor NF-YA away from its
target genes to undergo cell cycle arrest (Hung, Wang et al. 2011).. Another subtype lncRNA of
this class works directly with Pol II. An upstream minor promoter of dihydrofolate reductase
(DHFR) produces a lncRNA that inhibits assembling of pre-transcription elements at the major
promoter via a mechanism of forming DNA: ncRNA complex or binding general transcription
factor II (Martianov, Ramadass et al. 2007).
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LncRNAs can also affect the nuclear compartment. Nuclear enriched abundant transcript
1(NEAT1) associates with multiple paraspeckle proteins to stabilize paraspeckles (Chen and
Carmichael 2009; Clemson, Hutchinson et al. 2009). Metastasis-associated lung adenocarcinoma
transcript 1 (MALAT1), another very abundant lncRNA localized in nucleus, binds
serine/arginine splicing factors. MALAT1 accounts for relocating those splicing factor to
transcription start sites, where mRNA precursors get cleaved (Tripathi, Ellis et al. 2010).
LncRNAs could also exert their functions in post-transcriptional steps. MALAT1, Gomafu/MIAT
and some natural antisense transcript all play roles in mRNA splicing, as examples of posttranscriptional regulation (Sone, Hayashi et al. 2007). In addition to process mRNA, lncRNA
may even be able to impact mRNA stability and protein translation (Gong and Maquat 2011;
Yoon, Abdelmohsen et al. 2012). To date, lncRNA expression analyses predominately studied by
qPCR have reveled association between lncRNA dysregulation and diseases, most notably cancer.
Although most lncRNAs resides in the nucleus, a proportion of lncRNAs localize within or are
transported to cytoplasm to regulate proteins translation, localization or mRNA stability
(Kapranov, Cheng et al. 2007). LncRNA NRON prevents the traffic of nuclear factor of activated
T-cells (NFAT) transcription factor to nucleus from cytoplasm where it activates target genes in
response to calcium-dependent signals (Willingham, Orth et al. 2005) . Cytoplasmic lncRNAs
also are capable to base pair with mRNA and thereby regulate mRNA transcription and protein
translation. For example, UCHL1 mRNA antisense, which is a lncRNA, complements to UCHL1
AUG initiation codon and combined inverted SINEB2 domains to enhance UCHL1 protein
synthesis in cytoplasm(Carrieri, Cimatti et al. 2012); PTENP1, a pseudogene gene of tumor
suppressor gene PTEN, has the same microRNA binding sequences in 3’UTR as that of PTEN,
leading to a microRNA binding competition between PTEN and PTENP1, resulting in PTEN
gene activation and translation (Poliseno, Salmena et al. 2010).
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Table 1. Current cancer-related lncRNAs
lncRNA

Cancer

Molecular Function

Reference

HOTAIR

Multiple
cancers

Epigenetic regulation

MALAT1

Multiple
cancers

mRNA splicing

H19

Multiple
cancers

Epigenetic regulation

MEG3

Multiple
cancers

P53 activation

KCNQ1OT1

Breast, colon

Epigenetic regulation

Zfas1
Gas5

Breast
Breast,
pancreas
Multiple
cancer

NA
Decoy of glucorticoid
receptor(GR)
Decoy of microRNA

Prostate,
leukemia
NA

Epigenetic regulation

(Gupta, Shah et al. 2010; Kogo,
Shimamura et al. 2011; Yang, Zhou et al.
2011; Chen, Sun et al. 2013; Zhang, Han
et al. 2013)
(Ji, Diederichs et al. 2003; Luo, Ren et al.
2006; Yamada, Kano et al. 2006;
Fellenberg, Bernd et al. 2007)
(Hibi, Nakamura et al. 1996; Berteaux,
Lottin et al. 2005; Fellig, Ariel et al. 2005;
Tsang, Ng et al. 2010)
(Zhang, Gejman et al. 2010; Braconi,
Kogure et al. 2011; Jia, Wei et al. 2013;
Lu, Li et al. 2013; Sun, Xia et al. 2013)
(Tanaka, Shiota et al. 2001; Rodriguez,
Weng et al. 2011)
(Askarian-Amiri, Crawford et al. 2011)
(Mourtada-Maarabouni, Pickard et al.
2009; Lu, Fang et al. 2013)
(Panzitt, Tschernatsch et al. 2007;
Matouk, Abbasi et al. 2009; Zhao, Guo et
al. 2014)
(Yu, Gius et al. 2008; Yap, Li et al. 2010)

HULU

ANRIL
CCND1
BC200
PTENP1

Multiple
cancers
Prostate

PCA3
PCATs

Prostate
Prostate

Induced by DNA
damage
Protein binding
Decoy of microRNA
binding sites
NA
NA

(Wang, Arai et al. 2008)
(Chen, Bocker et al. 1997; Iacoangeli, Lin
et al. 2004)
(Poliseno, Salmena et al. 2010)
(Bussemakers, van Bokhoven et al. 1999)
(Prensner, Iyer et al. 2011)

Different expression of lncRNAs between cancer and normal tissue indicates the potential use of
lncRNA as a diagnostic and prognostic tool, and expanding understanding of its molecular
mechanisms also suggest avenues to treat cancer with lncRNA molecules. PCA3, for an instance,
has been tested in large controlled clinical settings, confirming the previous discovery of PCA3
differential expression pattern, about 60 to 100 times higher in cancer tissue than benign prostate
(Hessels, Klein Gunnewiek et al. 2003) . The effectiveness of PCA3 in diagnosing prostate cancer
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is about the same as that of prostate-specific antigen (Day, Jost et al. 2011). HOTAIR, as another
example, was found to be increased by hundreds of times in metastatic breast cancer tissues and
also shows a robust association with patient prognosis (Gupta, Shah et al. 2010). In addition to
breast cancer, HOTAIR was subsequently found to be associated with multiple cancers, including
colon cancer and hepatocellular carcinoma (Kogo, Shimamura et al. 2011; Yang, Zhou et al.
2011). Scientists also identified lncRNA MALAT1 as a prognostic factor for patients with nonsmall cell lung cancer and then validated it in endometrial stromal sarcoma of uterus and liver
cancer afterwards(Ji, Diederichs et al. 2003; Yamada, Kano et al. 2006; Lin, Maeda et al. 2007).
Ideally biomarkers should be sampled easily, for example, from body fluids. Previous
investigations have suggested some microRNAs are stable and detectable in blood, urine and
sputum, while very few lncRNAs examples have been elucidated in body fluids. HULC (highly
upregulated in liver cancer) is detectable in the blood of liver cancer and colon cancer patients by
conventional PCR and PCA3 is also a good biomarker in urine for prostate cancer as mentioned
above (Panzitt, Tschernatsch et al. 2007; Matouk, Abbasi et al. 2009). In addition to cancer,
lncRNAs aberrations were also found in other diseases including Alzheimer’s diseases, psoriasis
and heart diseases (Sonkoly, Bata-Csorgo et al. 2005; Faghihi, Modarresi et al. 2008;
Korostowski, Sedlak et al. 2012). LncRNA Beta-secretase 1 antisense (BACEAS), which
regulates Beta-secretase 1sense, exhibit enhanced expression in several regions of brains in
several patients with Alzheimer’s diseases (Faghihi, Modarresi et al. 2008). Moreover, lncRNA
psoriasis susceptibility-related RNA Gene Induced by Stress (PRINS) was named by its potential
relationship with psoriasis by recent study (Sonkoly, Bata-Csorgo et al. 2005).
LncRNAs might be also useful for therapeutics. Since lncRNA can recruit chromatin-modifying
complexes to silence gene expression, it might be possible to deliver specific lncRNAs by gene
therapy delivery systems though it could be risky. Moreover, lncRNA could also be recognized
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by synthetic siRNAs or microRNA. For example, H19 was successfully targeted by a plasmidbased RNAi system to advance treatment of bladder cancer and pancreatic cancer (Smaldone and
Davies 2010; Sorin, Ohana et al. 2012). Knockdown of prostate cancer noncoding RNA 1
(PRNCR1), which is upregulated in some prostate cancer, weakens the viability of prostate
cancer cells and androgen receptor transactivation activity (Chung, Nakagawa et al. 2011). Not
only being potential biomarkers or therapeutic agents, lncRNA could also be used to develop
novel therapeutic strategies. Synthetic lncRNAs might work as decoy of transcription factor or
microRNA, thus reduce transcription activity or microRNA expression, as Gas5 and PTENP1 do
(Mourtada-Maarabouni, Pickard et al. 2009; Poliseno, Salmena et al. 2010). To date lncRNA has
mostly been looked at by qPCR based and by RNA sequencing tests. However, a novel in situ
hybridization assay allows us to investigate lncRNA expression by microscopy.
Principle of RNAscope® chromogenic in situ hybridization assay
RNAscope® chromogenic in situ hybridization assay is novel RNA detection system use with
intact cells on either fresh or preserved tissues. Two independent probes (double Z probes) are
designed to hybridize to target sequence in tandem for signal amplification, which ensure
specificity because it has extremely low possibility that two probes will bind to non-specific
target simultaneously. The lower part of Z probe is 18 to 25 base region that is complementary to
target sequence and the higher part is a 14 base tail sequence that is designed to bind preamplifier. Two Z probes are connected by a spacer sequence and double Z probes are designed
specifically for each RNA target. Usually, 20 double Z probe pairs can cover 1 KB length of
target sequence. After double Z probes hybridize to target RNA sequence, a cascade of steps is
employed to amplify signals. Preamplifier first binds to higher region of double Z probes and then
amplifier bind to the 20 binding sites on each pre-amplifier. Label probes containing chromogenic
enzymes (horseradish peroxidase) are then applied to conjugate with the 20 binding site on each
amplifier. Finally, colored RNA molecules could be visualized by bright field microscope after
21

substrate application. The general scheme is displayed in Figure 1. Comparing with other RNA
in situ hybridization systems, RNAscope® technology holds several advantages: 1) it is a highly
sensitive platform because each RNA sequence only requires three double Z pairs to bind, so, 20
double Z probe pairs should target RNA molecule robustly even it is somehow degraded. 2) it is
highly specific because only simultaneous binding of two independent Z probes provide binding
site for pre-amplifier, while singe Z will not produce any binding site that prevent non-specific
amplification.

Figure 1. Work scheme of RNAscope® in situ hybridization assay

Conclusion
As a major cause of morbidity and mortality in women, breast cancer is one of the most critical
diseases internationally. Tremendous effort has been made in basic research and clinical trials to
investigate the molecular science of breast cancer and improve its diagnosis, prognosis and
treatment. However, there are some barriers remaining for this complex disease. With advanced
technologies, we need to pay more attention to discover useful biomarkers which can accurately
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classify subtypes of breast cancer, especially carcinoma in situ. Though DNA ploidy change has
been studied in FFPE samples previously, subtle intratumoral heterogeneity have not been studied,
which might contribute to the identification of various cancer signatures in combination with
multiparametric flow cytometry. In addition, very few investigators have used CISH to detect and
quantify lncRNA expression in breast cancer archived samples and very few prior studies have
looked at the connection between lncRNAs expression levels and breast histopathological
markers, which may be valuable for the purpose of breast cancer diagnosis and prognosis.
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Alternative Tissue Sampling Method to Detect Genetic Instability of Breast
Carcinoma with Flow Cytometry

Aim:
To test a novel approach for investigating DNA ploidy and intratumoral heterogeneity within
solid tumors by flow cytometric analysis
Hypothesis:
Core punch tissue sampling allows the targeted recovery of tumor tissues from FFPE specimens
for DNA aneuploidy and intratumoral heterogeneity analyses of breast carcinomas by flow
cytometry.
Material and Methods:
Tissue acquisition
FFPE tissue blocks of breast carcinoma were provided courtesy of Dr. Kavita Munjal
(Department of Pathology, Sri Aurobindo Institute of Medical Sciences, Indore, Madhya Pradesh,
India) and normal placenta specimens were retrieved from Fletcher Allen Health Care (FAHC),
Burlington, VT. Each breast carcinoma FFPE block was cut into 5µm section on microtome
(Leica, Allendale, NJ) subsequently stained with hematoxylin and eosin (H&E) in the FAHC
histology department. All H&E stained slides were reviewed and tumor regions were marked by
Dr. Donald L. Weaver from Department of Pathology, University of Vermont.
Tissue Sampling
Breast cancer FFPE blocks were placed in tissue arrayer (Beecher Instrument, Silver Spring, MD)
and 1mm diameter tumor tissue cores were punched from the blocks guided by the marked H&E
slides. 1mm normal placental tissue cores were punched from FFPE placental tissue blocks.
Cores were put on a piece of 50 micron nylon mesh provided by Advanced Genome Technology
Core (AGTC) in the University of Vermont and cut by knife to remove excess paraffin wax.
Then, tweezers were used to wrap the tissue core in nylon mesh that was then put it into
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micromesh biopsy cassettes (Thermo electron cooperation, Pittsburgh, PA). The mesh was
clamped down securely by the cassette lid to prevent the tissue cores from coming out of the
nylon mesh. Post-punch FFPE block tissue sections were recut for H&E staining in order to
confirm that core was correctly punched from tumor enriched regions.

Single cell suspension preparation
Several approaches were applied to deparaffinize tissue core and disaggregate cells in order to
make single cell suspensions. The overall schemes are similar including xylene deparaffinization,
ethanol rehydration and enzymatic treatment, but distinct treating durations and enzymes were
tested to generate the most effective approach. According to the optimal procedures, extracted
tissue core were placed into biopsy cassettes and then immersed into two changes of xylene
solution (Fisher scientific, Pittsburgh, PA) for two hours, respectively. Subsequently, two changes
of 100%, 95%, 70%, 50% ethanol (Pharmco-aaper, Brookfield, CT) were sequentially applied to
rehydrate tissue core in cassettes for twenty minutes each. After rehydration, the cassettes were
left in MilliQ DI water for one and a half hours to get rid of remaining ethanol. After that,
cassettes were opened carefully and tweezer was used to clamp mesh wrapped tissue core and
place it into a clean 1.5ml centrifuge tube. Subtilisin Carlsberg solution was prepared by adding
0.1%(w/v) Sigma Protease XXIV (Sigma, St.Louis, Mo) , 0.1M Tris, 0.07M NaCl to make a pH
7.2 solution, or by using a Protease XXIV kit (Biocare medical, Concord, CA); 500µl of the
solution was added into tubes for disaggregating cells of the tissue core at 37°C water bath
overnight. Next morning, Orbit LS shaker (Labnet International, Edison, NJ) was applied to
shake tubes for 20 mins after removing that tube from 37°C water bath. Then, Subtilisin
Carlsberg solution now containing the digested cells was filtered through fresh 50 micron nylon
mesh into a clean dark centrifuge tube for staining.
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Staining
For staining purpose, propidium iodide (PI), Sytox Green, SYBR Green and 4', 6-Diamidino-2Phenylindole, Dihydrochloride (DAPI) were used for comparison. PI solution (Sigma, St.Louis,
Mo) was diluted from 1.0mg/ml into 1.0µg/ml by adding 10mM Tris, 10um Nacl and 1ul Nonidet
P-40 water solution. And the prepared PI solution was mixed with Substilin Carlsberg solution in
equivalent amount in 1.5ml dark centrifuge tube to bind both double strand and single strand
nuclei acid. Appropriate Ribonuclease A (10µg RNase A/ 1ml PI solution -100µg RNase A /1ml
PI solution) was added up in order to get rid of single strand RNA. The tubes were then placed in
the dark fridge to incubate at 4 centigrade for 1.5 hours. Both SYBR Green (Life Technology,
Foster City, CA) and Sytox Green (provided by Dr. Yvonne Janssen-Heininger’s lab) were
required to add in 1X as the final concentration and the incubation situation was set at 4
centigrade for 30min in dark. DAPI (Life Technology, Foster City, CA) was firstly made 5mg/ml
stock solution in DMSO, which was diluted to 3µM in DAPI staining buffer (100 mM Tris, pH
7.4, 150 mM NaCl, 1 mM CaCl2, 0.5 mM MgCl2, 0.1% Nonidet P-40) and the specific
incubation situation for DAPI was 4 centigrade and 15 mins in the dark. After staining, all
solution was transferred from 1.5ml centrifuge tube to flow cytometry tube (either provided by
AGTC or the Department of Immunology at the University of Vermont).
Flow Cytometry
Two flow cytometers were utilized. Coulter EpicsXL-MCL (Beckman Coulter, Inc, Brea, CA) is
a flow cytometer located in the AGTC and was applied to cells suspension stained with PI, Sytox
Green and SYBR Green. Procedures recommended by operator manual were followed. The other
flow cytometer that was used is BD LSRII (Becton Dickinson, Franklin lakes, NJ) that locates in
Department of Immunology in University of Vermont. Sample tubes stained with Sytox Green,
SYBR Green and DAPI were detected by this cytometer. Procedures recommended by operator
manual were followed. At least 5000 intact nuclei were collected for plotting a DNA histogram.
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The diploid placental cells obtained from placental FFPE block were used as an external standard
which was analyzed firstly to adjust the voltage of the photomultiplier in order to fix the signal of
the diploid standard at channel position 50 and it was also measured after all the tumor samples.
Data analysis
FCS EXPRESS 4 FLOW CYTOMETRY – RUO [De Novo Software, Los Angeles, CA] was
used to analyze all EpicXL- MCL LMD file and BD LSRII FCS file. The DNA index (DI) was
defined as the ratio of the mean fluorescence channel number of the G0/G1 in tumor sample to
the mean fluorescence channel number of the G0/G1 in external control and the coefficient of
variation (CV) of the G0/G1 and G2/M peaks was defined as the normalized standard deviation
obtained by Gaussian curve fitting, both of which were analyzed by FCS EXPRESS 4 FLOW
CYTOMETRY – RUO. Besides, other parameters like G1 phase portion, G2 phase portion, S
phase portion and percentage of background aggregates debris (B.A.D) were also measured. The
best fitting curve was selected from six analysis models that already exist in software. For this
study, a DI between 0.95-1.05 was defined as DNA diploid, and any DI < 0.95 or > 1.05, as
aneuploidy (Corver, Ter Haar et al. 2011). To assess intratumoral DNA content heterogeneity,
multiple cores were punched from individual FFPE tissue blocks identified by H&E review as
containing sufficient tumor enriched regions. Within-assay coefficient of variation, which was 2%
for DNA index analysis and 7% for %SPF analysis, was calculated with 10 cores from a placental
FFPE block to confirm the limits for valid intratumoral heterogeneity. The assessment of
intratumoral heterogeneity was defined by either a difference of the DNA-ploidy pattern or a
variation of >8% (±2 x CV) in the DNA index among aneuploid patterns between tumor
subpopulations in separate regions, or S-phase fraction difference >28% (±2 x CV) regarding
lowest DNA index among all samples as the reference. DNA content intratumoral heterogeneity
statistical analyses (Fisher’s exact test) were performed using GraphPad InStat (GraphPad
Software, Inc., La Jolla, CA).
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Results:
The optimization of single cell suspension
To determine which enzymes is better to disaggregate single cells from tissue core, 0.5% trypsin
solution and 0.1% Subtilisin Carlsberg solution were applied for 1mm tissue cores that was
punched from archived breast carcinoma FFPE tissue blocks in Experimental Pathology lab, and
compared, following same deparaffinization and rehydration procedures. PI was used as DNA
binding dye in both tests. Figure 2 shows the better applicability of Subtilisin Carlsberg for cell
releasing.
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Figure 2. Comparison of different digestion enzymes
Tissue core were treated with 0.5% trypsin (A) and 0.1% Subtilisin Carlsberg (B) and subsequent flow
cytometric analysis were compared. PI was used as binding dye for all tests and RNase A was applied to
eliminate RNA binding.

Then, we assessed different combinations of deparaffinization and enzymatic digestion to
optimize the time for disaggregating cell. 1mm placental tissue core were used as our sample and
PI was used for DNA binding dye. Figure 3 shows de-wax and digestion time data. In brief, a 4h
xylene dewaxation step plus overnight digestion rinse resulted in a histogram with a distinct and
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narrower peak with a lower CV than a 2h xylene dewaxation plus shorter time of incubation (data
not shown).
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Figure 3. Comparisons between deparaffinization time and enzymatic digestion time
Four combinations of xylene diparaffination and subtilisin carlsberg digestion, differing in length, were
tried and compared: 4 hours dewaxing plus overnight enzymatic digestion (A); 2 hours dewaxing plus
overnight enzymatic digestion (B); 2 hours dewaxing plus 2 hours enzymatic digestion (C); 4 hours
dewaxing and 2 hours enzymatic digestion (D). Propidium iodide (PI) was used as binding dye for all tests
and RNase A was applied to eliminate RNA binding.
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DNA Binding affinitiy is another factor that influences flow cytometry. Four binding dyes: PI,
SYTOX Green, SYBR Green and 4',6-diamidino-2-phenylindole (DAPI) were compared and two
flow cytometers were used. Coulter EpicsXL-MCL was applied to only assess affinity of DNA
binding with only PI, SYTOX Green and SYBR Green as it lacks apporporite detector for DAPI ,
as Figure 4 upper panel shows, suggesting a better applicablity of SYTOX Green and SYBR
Green, while BD LSRII flow cytometry was subsequently used to compare SYTOX Green,
SYBR Green and DAPI. Figure 4 low panel disaplys DAPI is the best among three.
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Figure 4. Comparisons of different DNA binding dyes
PI (A), SYTOX Green (B), SYBR Green (C) DNA binding affinity was tested with Beckman Coulter
EpicsXL-MCL; DAPI (D), SYBR Green (E), SYTOX Green (F) DNA binding affinity was assessed by BD
LSRII. RNase I was added with PI to eliminate RNA binding
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To verify our temporary conclusion that DAPI was the most appropriate dye, we set up another
test to compare the results that SYBR Green produced with two flow cytometers to exclude any
bias on machines. Figure 5 demonstrates that BD LSRII generated result is much better than that
of Beckman Coulter EpicsXL-MCL with the same DNA binding dye, suggesting DAPI would be
the best option for our subsequent analysis.
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Figure 5. Comparisons of two flow cytometers
SYBR Green was used as DNA binding dye to compare flow cytometry results generated by each flow
cytometers: Beckman Coulter EpicsXL-MCL (A) and BD LSRII (B)

The application of novel core punch sampling method to show DNA ploidy
Of the 31 breast carcinoma specimens (1 DCIS, 1 medullary, 1 invasive ductal
carcinoma/invasive lobular carcinoma, 2 pure invasive lobular carcinoma, 26 pure invasive ductal
carcinoma), 23 (74%) were shown as aneuploidy by our novel sampling method, while 8 (26%)
were diploidy. Pre-punched and post punched H&E stain slides was made to confirm proper
tissue selection, as Figure 6 showed. Figure 7 exhibits various aneuploidic examples.
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Figure 6. Identification and sampling of tumor rich regions in FFPE tissue blocks
(A) Hematoxylin and eosin (H&E) stained slide marked for tumor (blue line) and normal cell regions
(black line). (B) Post-punch FFPE block. (C) Pre-punch H&E stained tumor (D) Post–punch H&E to
confirm accurate sampling
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Figure 7. DNA content profiles from selected individual core punch samples
(A) FFPE normal placental cells with DI=1.00. (B) Tumor adjacent normal cells DI=1.00, showing the
correspondence of normal DNA content profiles from breast and placenta tissues. (C) DNA content
histogram showing a hyperdiploid tumor with DI=1.72. (D) Multiploid tumor showing hyperdiploid
(DI=1.08 [grey]) and hypodiploid (DI=0.72 [blue]) populations. (E) Hypertetraploid tumor with DI=2.67.
(F) Diploid tumor DI=1.00.
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The application of our novel core punch sampling method: to detect subtle intratumoral
heterogeneity
Among all 31 specimens, 23 tumors had sufficient tumor for 2 or more core-punches, 3 (13.0%
[all IDC: 1 moderate, 1 poorly differentiated]) showed diploidy only; 20 (87.0% [3 moderately,
17 poorly differentiated]) were aneuplodic: 10 (43.5%) showed no significant variation in DI and
10 (43.5%) showed DI intratumoral heterogeneity; 11 (47.8%) showed %SPF intratumoral
heterogeneity, 7 (30.4%) showed both DI and %SPF heterogeneity. Figure 8 displays 2 cases with
intratumoral DNA index heterogeneity and 1 case with intratumor S-phase fraction heterogeneity.

Figure 8. Intratumoral DNA heterogeneity demonstrated by core punch tissue sampling
Histogram group A and B generated by cores in the same tissue block showing DNA index heterogeneity
with (A1) DI=1.71 vs. (A2) DI=1.39; (B1) DI=1.47 vs. (B2) DI=1.62. Intratumor percentage S-phase
fraction heterogeneity (C1) %SPF=12.61 vs. (C2) %SPF=27.01.
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Statistical analysis
Patient ages ranged from 35 to 95 years (mean 52.1); tumor size from 10 to 80 mm (mean 37.0);
tumor stage 1 (n=7), 2 (n=15), 3 (n=5), 4 (n=4); ER positive 17 (54.8%), ER negative 14 (45.2%);
PR positive (64.5%), PR negative 11(35.5%); HER2 positive 10 (32.3%), HER2 negative 21
(67.7%). There were no significant differences (P>0.05) of DI and/or %SPF intratumoral
heterogeneity with reference to any of these parameters.

Discussion:
The main findings of this study are two-fold: firstly, that core-punching is an effective method for
sampling cells from FFPE specimens for flow cytometric DNA content analysis, and secondly
that DI and %SPF intratumoral heterogeneity are relatively common events in breast tumors even
within focal tumor localized within a single surgical block.
Previous FFPE specimen studies have assessed DNA content from intact nuclei recovered from
≥50 µm whole tissue sections prepared by microtomy. Thick sections are required as DI index
and the proportion of cells scored as aneuploidic increases significantly comparing sections cut to
a thickness of 5, 10, 20, 40, or 80 mm and the thinner the section the greater the cellular debris
generated (Kallioniemi 1988). Punching recovers 1 mm diameter cores through the depth (up to
several millimeters) of a tissue block and as such is a highly effective approach for recovering
intact nuclei. Besides, with the margined tumor rich regions on tissue blocks, punching targets
much more specifically on tumor cells instead of including abundant normal adjacent cells around
by cutting whole sections that possibly lower or remove comparative tumor cell population
proportion in our scale (Figure 9). The potential disadvantages are the assumption that tumor
identified at the block surface is present through the depth and the lack of ‘internal control’
normal diploid cells in a tumor rich region; whole sections are more likely to contain sufficient
control reference cells; however, the very presence of these cells also impair DNA
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content/aneuploidy assessment (Hedley, Friedlander et al. 1983). The tissue blocks available for
this study lacked high cellularity normal adjacent tissues. FFPE normal placental tissue was used
instead and its status as a viable diploid control confirmed by comparing multiple (10) cores to
confirm consistent DNA content measurement. The core approach was then used to investigate
intratumoral DI and %SPF values within a surgical block: heterogeneity was found in 43.5% and
47.8% of breast tumors respectively.
Several previous studies have investigated DNA content heterogeneity comparing different
samples of gross dissected fresh tumors or serial FFPE sections or sections from alternative
blocks (Table 2). Assay of multiple samples is recommended to detect aneuploidy; for example,
Bergers and his colleagues (Bergers, van Diest et al. 1996) reported that at least six separate areas
required measurement in order to fully detect heterogeneity. In the present study, tumor within an
FFPE block was sampled at 2-3 tumor rich sites. The heterogeneity detected is within the range
found in previous studies (Table.15). Practically, this shows that selective core punching of tumor
regions requires less extensive tissue usage to reveal heterogeneity than a whole section approach.
Biologically, these data show that even DNA content heterogeneity can be a highly localized
event within a tumor.
With the advent of improved dyes and instrumentation, there has been a resurgence of interest in
the use of flow cytometry for the analysis of FFPE specimens. Multiparametric techniques enable
combined DNA content and protein biomarker assay through the combined use of labeled
antibodies (Corver and ter Haar 2011; Dayal, Sales et al. 2013). Multiparametric approaches in
conjunction with core punching will likely provide more refined data than is possible from a
whole section approach. Studies investigating the relationship of DNA content heterogeneity to
other markers of genomic instability such as mutations, deletions, insertions, and translocations
are warranted.
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Figure 9. Comparison of core punching and whole section tissue sampling method
One FFPE tissue block was sampled by cutting whole section (A) and alternative punching method (B),
stained by DAPI and compared by BD LSRII flow cytometer. Normal adjacent cells were drawn in black
and tumor cells were depicted in grey.
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Table 2. DNA content heterogeneity reported in previous studies
Author

Tumors
n

(Prey, Meyer et al. 1985)

8

(Kallioniemi 1988)

Samples
n

DNA index
heterogeneity rate (%)

SPF
heterogeneity rate (%)

5–11

67

-

104

3–10

13

36

(Meyer and Wittliff 1991)

61

2–31

26

-

(Bonsing, Beerman et al.
1993)

18

1–11

67

(Schvimer, Lash et al. 1995)

28

3

43

-

(Danesi, Spano et al. 1997)

102

Not given

28

-

(Arnerlov, Emdin et al.
2001)

48

4–5

44

The present study

23

2–3

44

-

71
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Conclusion:
The first study demonstrates that a core-punching method is effective to release cells from FFPE
tissue specimens for flow cytometric DNA content analysis, which is a standard techniques to
detect abnormal cell in terms of either chromosome abnormalities or disordered cell cycle. The
composite analysis of the results from this investigation well illustrates that this alternative tissue
sampling method is able to release intact single cell for flow cytometry from one 1mm diameter
tissue core punched in depth from preserved tissue blocks. We were able to perform flow
cytometric analysis with this new method to reveal both normal and abnormal DNA ploidy.
Comparing with typical whole tissue sections cell releasing strategy, this new technique can
provide more accurate tumor cell ploidy status without taking much adjacent normal cells into
account. More importantly, by using current method, we identified intratumoral heterogeneity
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either in DNA content or S phase fraction, from different cores that were retrieved from single
surgical blocks, indicating even within a single piece of solid tumor, tumor cell populations may
come from distinct clones and undergo complicated mutations along tumor develops. Our
findings can provide some insights not only for breast cancer biomarker discovery that looks for
precise DNA abnormality pattern, but also for breast cancer therapeutics regarding intratumoral
heterogeneity. Although internal control is lacking, external control normal placental cells seems
to be a good surrogate.
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Long non-coding RNA Chromogenic in situ Hybridization Signal Patterns Correlate
with Breast Tumor Pathology

Aim
To apply a novel RNA in situ hybridization detection technology for the investigation of lncRNA
expression in FFPE specimens and to assess the relationship between six lncRNAs and common
breast tumor markers using tissue microarrays.

Hypothesis
RNAscope® CISH can be used to substantiate lncRNAs identified as potential markers of breast
cancer by qPCR or RNA sequencing studies.

Material and Methods
Tissue microarray (TMA) preparation
All FFPE tissue blocks of breast carcinoma and DCIS were retrieved from FAHC archives. FFPE
blocks were recovered for 52 patients identified by electronic record search by pathology
residents Drs. Daniel Olsen and James deKay as having concurrent DCIS and invasive breast
cancer (IC). Each FFPE block was sectioned, stained by H&E and subsequently reviewed by Dr.
Donald L. Weaver. Regions of DCIS, IC and normal adjacent epithelia (NA) were marked on the
slides and used to guide core punching (one core punch per NA, DCIS or IC region per patient)
for the construction of the TMAs from the companion FFPE surgical blocks. A tissue arrayer
(Beecher instrument, Silver Spring, MD) was used to prepare tissue microarray FFPE blocks. A
one millimeter diameter receptor needle was used to extract cores from a FFPE block and relocate
it into a recipient paraffin block. Tissue cores from same individuals were made in the same
horizontal line, separated by tissue types. Five tissue microarray FFPE blocks were made by this
technique and each block contained about ten invasive cancer spots, ten DCIS spots and ten NA
tissue spots with one separated head and neck tumor tissue spot as location control (line 1, 3, 5, 7,
9), as shown in Figure 10. Five TMA blocks were placed in Thelco® laboratory oven (Jouan, Inc.,
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Winchester, VA) to incubate overnight at 60℃. One section of five micrometer tissue section of
each TMA block was cut, stained and reviewed by pathologists in FAHC.

A

B

Figure 10. Tissue microarray design
A) diagram of tissue microarray block; B) actual TMA

LncRNA in situ hybridization process
Five micrometer tissue slides were made and baked in Thelco® laboratory oven (Jouan, Inc.,
Winchester, VA) overnight at 60℃. Generally, RNAscope® FFPE in situ hybridization assay
platform (Advanced Cell Diagnostic, Hayward, CA) was applied in our study with minor
modification on pre-treatment steps. The optimal procedures were listed in a flow diagram in
figure 11. Positive control POLR2A (P/N 310451, Advanced Cell Diagnostic, Hayward, CA) and
negative control DapB (P/N 310043, Advanced Cell Diagnostic, Hayward, CA) were tested for
each lncRNA probe. To ensure the RNA targeting specificity of ACD lncRNA probes, we applied
an additional RNase A (Sigma-Aldrich, St. Louis, MO) treatment step and DNase I (Sigma42

Aldrich, St. Louis, MO) treatment step right after pretreat 3 and compare the results to that of
regular procedures. RNase A was diluted to 100µg/ml in phosphate buffered saline (PBS)
(Sigma-Aldrich, St. Louis, MO) and then 100µl RNase A solution was applied to cover and
incubate tissue section for thirty minutes at room temperature, followed by Milliq water washing
for five minutes for three times. Similarly, 50µg/ml DNase I work solution was mixed by DNase
I, 10x DNAse I reaction buffer (P/N y02340, Invitrogen, Carlsbad, CA) and Buffer AE (Qiagen,
Valencia, CA) and 100µl DNase I work solution was added to cover and incubate tissue section
for fifteen minutes at room temperature. Three times of Milliq water washing for five minutes,
respectively were followed to get rid of excessive solution.
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Figure 11. Work flow of modified RNAscope FFPE in situ hybridization assay
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Immunohistochemistry
Three antibodies (EZH2 (D2C9) XP(R) Rabbit mAB: Cell Signaling, Danvers, MA; p53 (Y5):
Thermo Fisher Scientific, Waltham, MA; CDKN1C/p57 antibody [EP2515Y], N-term: GeneTex,
Irvine, CA) were tested on five tissue microarray slides. Several tests were done to optimize
antigen retrieval time, antibody concentration and antibody hybridization duration, which usually
varies depends on antigens. The overall protocol is similar to standard chromogenic
immunohistochemistry with HRP protocol that was established by Experimental Pathology
laboratory of the University of Vermont, including deparaffinization, antigen retrieval, nonspecific antigen block, primary antibody hybridization, secondary antibody incubation, DAB
staining and counterstain. The general processes are shown in figure 12.
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Figure 12. Work flow of immunohistochemistry
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RNA in situ hybridization/ Immunohistochemistry evaluation criteria
Both RNA and protein markers expression level were scored. Two score systems were used:
visual scoring system and RNAscope SpotStudioTM software scoring system. Visual scoring
system has been well established for years to assess immunohistochemistry and in situ
hybridization stain, so all our markers were scored by eye. RNAscope SpotStudioTM software is a
automated, semi-quantitative scoring software that specializes in scoring RNAscope based
images. Since it was designed to only recognize and analyze punctate dot, it was only used to
provide score for lncRNA HOTAIR and KCNQ1OT1.


Visual scoring system
RNA markers

Bright field microscope was used to evaluate stain by experienced pathologist, Dr. Donald
Weaver. According to various staining patterns, different scoring criteria were applied and an
overall stain grade (SG) was generated by adding up all subgrades. Besides overall stain grade,
we also categorized lncRNA and protein markers expressions into 1) four scale patterns,
including negative, weak positive, moderate positive and strong positive and 2) two-tiered
dichotomous score, which represents low and high expressional group. For HOTAIR, three
variables: stain intensity, copy number per cell and stain proportion, were used. Stain intensity
was divided into two levels, which are low to medium and medium to high, and was assigned
score of 1, 2, respectively. Copy number per cell was stratified into low (1) and high groups (2)
based on visual experience and three copies per cell was the cut-off value. Upon stain proportion,
a generic rule was used for all RNAs and proteins except for lncRNA H19 because of its special
staining format. We gave a case score of 0 once it was not stained or it only had positive stained
cells less than 10%; score of 1 was given if one case had about 10-50% positive cells; 2 was
assigned if it had positive cells ranging from 50-75% and 3 was for cases which had more than 75%
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cells positive. So, by adding up three subgrades, the overall stain grade for HOTAIR ranged from
2 to 7. Similar to HOTAIR, we applied intensity, copy number per cell and stain proportion to
assess KCNQ1OT1. The only difference was the cut off value of copy number per cell in
KCNQ1OT1 was 2, which meant any cases with majority cell stained more than 2 copies was
called high, and vice versa. Therefore, the overall stain grade of KCNQ1OT1 was ranged from 0
to 7. We assessed H19 by copy intensity and proportion. Copy density was given from 0 to 3,
which represents negative, low, medium and high, and proportion was given from 0 to 3, showing
four different portion levels: negative, dots, patchy and diffuse. Thus, the overall score of H19
was from 0 to 6. MEG3 was assessed by stain intensity, which we assigned 1, 2, 3 to low,
moderate and high intensity, respectively, and stain proportion, which was the same as that of
HOTAIR and KCNQ1OT1. In general, stain grade of MEG3 was from 0 to 6. Regarding fourtiered scoring pattern for HOTAIR and KCNQ1OT1, any case with at least two of three scoring
variables in lowest end were weak positive, any cases with high copy number, strong stain, and
more than 50% of cells stained were in strong positive. The rest cases were all in moderate
positive category. For H19 and MEG3, any subjects with both two scoring variables scored no
greater than 1 were weak positive, subjects scored more than 5 were strong positive, indicating
one of the two variables must be highest and the other should be at least second highest, while the
others were all moderate positive. However, KCNQ1OT1, H19 and MEG3 had another group of
negative case. Additionally, we dichotomized all markers into low and high group to further
reduce categories. To HOTAIR, we gave 0 to low HOTAIR group, in which cases with score of
2-3, and 1 to cases with score of 4-7, suggesting any case with at least two of three scoring
variables in lowest end were low and the others were high. To KCNQ1OT1, the rationale of twotiered system was both negative cases and any positive subject had all three scoring variables in
lower end were given a 0, while others were 1. To H19, cases which either were negative or had
low copy density with signal as dot, was in low and the rest were in high group. To MEG3, the
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cut off value is 1, indicating a case that either were negative or had weak stain in less than 10%
cells was 0.
Table 3. Visual scoring system for lncRNA
a) HOTAIR
stain intensity
HOTAIR

low – medium
1

copy number
per cell
0-3
>3
1
2

medium –high
2

stain proportion
<10%
0

10%-50%
1

50%-75%
2

>75%
3

b) H19
H19

low

copy intensity
medium

high

dot

1

2

3

1

stain proportion
patchy
diffuse
2

3

c) KCNQ1OT1
stain intensity
KCNQ1OT1

low – medium
1

medium -high
2

copy number
per cell
0-2
>2
1
2

stain proportion
<10%
0

10%-50%
1

50%-75%
2

d) MEG3
MEG3

low
1

stain intensity
Medium
High
2
3
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<10%
0

stain proportion
10-50% 50-75%
1
2

>75%
3

>75%
3

Table 4. Four tiered pattern and dichotomous scoring system of lncRNA
lncRNA

Dichotomous scoring system

Four tiered scoring system

Neg
W
M
S
Low group (score=0)
High group (score=1)
SG=2-3
SG=4-5
SG=6-7
HOTAIR
SG=0
SG=2-3
SG=4-7
SG=1-2
SG=3-4
SG=5-6
H19
SG=0
SG=0-2
SG=3-6
SG=2-3
SG=4-5
SG=6-7
KCNQ1OT1 SG=0
SG=0-3
SG=4-7
SG=1-2
SG=3-4
SG=5-6
MEG3
SG=0
SG=0-1
SG=2-6
Neg= negative; W= weak positive; M= moderate positive; S= strong positive; SG=stain grade



Protein markers

We applied similar scoring system to assess protein makers. EZH2 was assessed based on
intensity and proportion as MEG3. Intensity was categorized into low, moderate and high with a
score of 1, 2 and 3, respectively; Proportion was set as other lncRNAs. The overall stain grade of
EZH2 ranged from 0 to 6 and pattern was segregated into negative (SG=0), weak positive (1-2),
moderate positive (3-4), strong positive (5-6). For further simplification, stain grade of 1 was
used as cut off value in EZH2 and rationale is same as MEG3. Other protein markers belong to
clinical markers, including ER, PR, Her2, Ki67 and p53, so we scored them from a clinical
perspective and dichotomized them into positive and negative. For ER, any case with more than
10% cells expressed ER was called ER positive, and so does PR; For Her2, score was given to
each case from 0 to 3 based on Her2 expression level. Any case with a score of 0 or 1 was
considered as Her2 negative, while cases with a score of 3 were called Her2 positive.
Confirmation of Her2 status by dual color in situ hybridization was undergone once we found
Her2 score of 2 by immunohistochemistry. For Ki67, 15% was the cutoff point, suggesting Ki67
positive was given to those cases with more than 15% cells expressed Ki67 protein. Ki67 protein
was scored as 1 to 4 based on percentage of cells that were stained: <5%=1; 5-10%=2; 1015%=3, >15%=4. P53 status was simply defined by whether it was stained or not.
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Table 5. Visual scoring system for EZH2
EZH2



low
1

stain intensity
Medium
High
2
3

<10%
0

stain proportion
10-50% 50-75%
1
2

>75%
3

Other clinicopathological factors

Other clinical information including DCIS nuclear grade, Nottingham grade, invasive tumor size,
invasive lymph nodes and lymphovascular invasion (LVI) status were recorded in original
diagnosis. In order to simplify variables that are continuous or have multiple groups, we stratified
them into fewer groups. We dichotomized DCIS nuclear grade to 1 that represents cases with an
original DCIS grade of 3, and 0 that represents any cases with a score less than 3, instead of
having original five grades (1, 1-2, 2, 2-3, 3). Nottingham grade was initially scored from 3 to 9,
while we applied three-tiered histological grade on Nottingham scores based on the following
way: grade 1 tumors have a total score of 3-5; grade 2 tumors have a score of 6-7; grade 3 tumors
have a score of 8-9. In terms of invasive tumor size, we trichotomized in the following way: 1
represents in a tumor less than 2cm, 2 represents in a tumor between 2cm-5cm, 3 stands for all
cases with a tumor greater than 5cm. Subsequently, we dichotomized tumor size with a cutoff
value of 2: any invasive lesion smaller than 2cm was assigned as 0, while any lesion bigger than
2cm was assigned as 1. Invasive lymph node was also dichotomized based on its status: any case
with a positive invasive lymph node was scored as one, and vice versa. LVI status was
dichotomized originally.
RNAscope® SpotStudioTM software
In order to apply RNAscope software to provide semi-quantitative results for individual case, all
TMA slides were firstly scanned by Ventana® iScan Coreo system ( Ventana Medical System,
Inc. Tucson, AZ) with high definition (HD) resolution. Scanned images of HOTAIR and
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KCNQ1OT1 were then imported to RNAscope SpotStudioTM software as a JP2000 file for further
analysis. The other lncRNAs were ineligible for this assessment for reasons of high (MALT1) or
negligible (Zfas1) expression or stromal expression (H19 and MEG3). In terms of settings, for
both lncRNAs, we kept default settings for image resolution that was 0.25, nucleus nucleus
diameter that was 7.5µm and spot diameter which was 1.2µm since they all fit our cases well.
Parameters of hematoxylin stain and spot stain were adjusted to better delineate cell regions and
recognize brown spots. For HOTAIR, spot diameter of 1.2µm was selected after previews and
kept for all cases to guarantee consistency for analysis. However, we optimized hematoxylin
stain parameter for each sample due to different background hematoxylin stain. We applied lower
hematoxylin stain level to those cases which had lighter nucleus stain and vice versa. For
KCNQ1OT1, 1.2µm spot diameter was also selected to all our samples and we repeated
optimizing hematoxylin stain parameter case by case. The range of hematoxylin stain value was
from 0.05 to 0.15. Regions of interest, which was primarily regions that would be analyzed, were
selected manually with the settings we optimized. An average of three to four regions of epithelia
cells in each case, were delineated manually for software calculations. We also revised on regions
of interest we selected by manually deleted those cells which were fake epithelia cells or have
fake spots in that area once after batch run to avoid bias. Once we satisfied, we exported the
results part and thus we were able to see what score of estimated spots per cell the software
calculated.
Data analysis
All statistical tests were performed with SYSTAT version 11. The comparisons of lncRNAs
expression level (lncRNA score, pattern RNAscope® software results) between different tissue
types were analyzed by non-parametric Friedman two-way analysis of variance (ANOVA). It was
firstly applied to test lncRNAs expression difference in cases containing all three tissue types. On
the ground of P value < 0.05, subsequent paired comparisons between each two tissue types were
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tested with the same method. The correlations between lncRNA expression and
clinicopathological factors in both DCIS and invasive cancer were analyzed by Pearson
correlation test and non-parametric tests, Mann-Whitney U test for two groups and KruskalWallis one-way analysis of variance (ANOVA) test for groups >3. Unadjusted pearson
correlation coefficient was tested on the null hypothesis that there is no correlation between
variables in order to highlight potential associations (p< 0.05) and subsequent Kruskal-Wallis test
or Mann-Whitney test were used to further analyze associations. Since Kruskal- Wallis evaluates
only evaluate differences in mean ranks to assess the null hypothesis that the medians are equal
across the group, Pearson Chi-square test and Fisher’s exact test were used to compare
proportional difference across groups, most for dichotomized variables. Variables with P value <
0.05 in univariate analysis were also used in the subsequent multivariate logistic regression test.
Spearman rank correlation tests were used to assess whether RNAscope® SpotStudioTM software
can produce consistent lncRNA score as eye scoring system.

Results
Sample size and clinical information
Tissue microarray contains total of 36 NA breast tissue, 34 DCIS tissue and 43 invasive breast
tissue collected from 46 patients. 2 of 46 patients were diagnosed as lobular carcinoma in situ
(LCIS), which were excluded in our study. Patient ages ranged from 30 to 86 years (mean 58.4);
tumor size from 0.04cm to 13.5cm (mean 1.8cm); DCIS nuclear grade 1(n=1), 1-2(n=4), 2(n=26),
2-3(n=2), 3(n=11), invasive Nottingham histologic score from 4 to 9 (mean6.2). Invasive
histological tumor grade was determined by Nottingham histologic total score based on criteria
mentioned previously: grade 1 (n=17); grade 2 (n=12) and grade 3 (n=13). Thus, our sample
contains invasive tumor grade 1(17), 2(n=15), 3(n=12). Positive lymph node was detected in
13/36(36.1%) and positive lymphovascular invasion (LVI) was found in 15/44(34.1%). In DCIS,
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ER, PR and Her2 statuses were also evaluated in our study by IHC, while their statues in invasive
cancer were recorded when patients received diagnosis. In DCIS, we had ER positive
26/30(86.7%), PR positive 24/30 (80%), Her2 positive 3/16 (18.8%), hormone receptor positive
26/30(86.7%), triple negative 1/16 (6.3%); In invasive cancer, we had ER positive 40/44(90.9%),
PR positive 36/44(81.8%), Her2 positive 5/43(11.6%), hormone receptor positive 40/44(90.9%),
triple negative 3/43(7.0%). Ki67 and p53 were stained by immunohistochemistry and
dichotomized. Ki67 positive were 6/18(33.3%) and 13/35(37.1%) in DCIS and invasive cancer,
respectively, while p53 positive were 2/20 (10%) in DCIS and 2/33(6.1%) in invasive cancer. A
summary of patient clinicopathological characteristics is shown in Table 6.
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Table 6. Summary of patient clinicopathological and molecular markers characteristics
Variables
Age(years)
Range
Mean

Value
30-86
58.4

DCIS nuclear grade
1
1-2
2
2-3
3

1 (2.2)
4 (9.1)
26 (59.1)
2 (4.5)
11 (25)

Invasive histologic grade
1
2
3

17 (38.7)
15 (34.1)
12 (27.2)

Lymph node status
Positive
Negative
NA

13 (29.5)
23 (52.3)
8 (18.2)

Tumor size (cm)
Range
Mean

0.04-13.5
1.8

lymphovascular invasion status
Positive
Negative

15 (34.1)
29 (65.9)

Molecular markers (DCIS)
ER positive
PR positive
Her2 overexpression (IHC + CISH)
Triple negative (ER-/PR-/Her2-)
Ki67 positive
P53 positive

26 (86.7)
24 (80)
3 (18.8)
1 (6.3)
6 (33.3)
2 (10)

Molecular markers (invasive cancer)
ER positive
PR positive
Her2 overexpression (IHC + CISH)
Triple negative (ER-/PR-/Her2-)
Ki67 positive
P53 positive

40 (90.9)
36 (81.8)
5 (11.6)
3 (7)
13 (37.1)
2 (6.1)
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Demonstration of tissue cores on TMA
When construct TMA, normal adjacent breast, DCIS and IC tissue regions were marked on
original H&E slides to guide core punch. To reconfirm tissue specificity on TMA, 5 microarray
blocks were cut to make 5µm slides, stained with H&E, and then reviewed by pathologists (DL).
Within NA tissue cores on TMA, several tissue cores only containing collagen and (or) adipocyte
were excluded in HOTAIR and KCNQ1OT1 analysis but not in H19 and MEG3 because both
H19 and MEG3 was stained mostly in stromal interspace while the rest two lncRNAs were all
found in epithelia cells. And quite a few tissue cores which were supposed to be pure DCIS or IC
ended up with a mixture of DCIS and IC, which were graded and recorded separately. Tissue core
H&E stains were displayed in Figure 13.

A

B

20µm
20µm

D

C

20µm
20µm

Figure 13. H&E stain of tissue cores
Image represents H&E stain of different tissue cores on TMA, (A)normal adjacet tissue; (B)DCIS tissue;
(C) invasive cancer tissue; (D) mixture of DCIS and invasive cancer tissue(Left: invasive; Right: DCIS).
All images were taken with 10X objective. [Scale bar: 20 µm]
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Detection of lncRNA by RNAscope® chromogenic in situ hybridization assay (CISH)
To ensure the lncRNA targeting specificity of RNAscope® assay platform, RNase A and DNase I
digestion steps were performed to all lncRNA probes and compared with standard staining
procedures. We confirmed that RNAscope® in situ hybridization assay was able to detect all
lncRNAs properly on FFPE tissue slides with standard staining procedures or even plus an
addition of DNase I treatment, however, lncRNA cannot be stained after RNase A treatment step
which intends to remove all ribonucleic acid. Two illustrations are shown in Figure.13.
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A

C

B

20µm

20µm

E

D

20µm

F

20µm

20µm

20µm

Figure 14. RNAscope® in situ hybridization assay specifically detect RNA molecules
Images (A-C) shows the detection of H19 in invasive caner tissue, by standard CISH(A) by standard CISH plus a step of DNase I digestion (B by
standard CISH plus RNase A treatment (C). Images (D-F) shows the detection of KCNQ1OT1 in invasive cancer tissue, by standard CISH (D); by
standard RNAscope® CISH plus DNase I digestion (E) by standard CISH plus RNase A treatment (F). All images were taken using a 10X objective.
[Scale bar: 20 µm]
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Long non-coding RNA staining results
 HOTAIR
HOTAIR staining was widely present as single of multiple dots in epithelia cell nuclei in all three
tissue types. Within TMAs probed with HOTAIR, 26 NA tissue regions, 25 DCIS regions and 32
invasive cancer tissue regions were scored by eye and RNAscope® SpotStudioTM software.
HOTAIR expression level between different tissue types were compared within same individuals
for patients who had two or three tissue spots. For HOTAIR, 11 patients had all three tissue types,
15 patients kept NA breast tissue and DCIS, 20 patients kept NA and invasive breast cancer
tissues, and 17 patients had both DCIS and invasive cancer tissues. In NA breast tissue, HOTAIR
was scored from two to five: 2(n=2), 3(n=21), 4(n=1), 5(n=2) with a mean of 3.42 by eye and in
terms of pattern distribution of HOTAIR in NA breast tissue, 23 cases were weak positive and
only 3 cases were moderate positive. By RNAscope® SpotStudioTM software, HOTAIR scores
varied from 0.07 to 1.25 with a mean of 0.54 in NA breast tissue. In DCIS regions, HOTAIR was
given a score by eye from 3 to 7: 3(n=4), 4(n=5), 5(n=7), 6(n=4), 7(n=5) with a mean of 5.04.
Four of them were weak positive, twelve were moderate positive and the rest nine were strong
positive. From the perspective of software, 0.1 was given as the minimum while 13.78 was given
as the maximum and the mean value was 2.17. In invasive tissues, they had HOTAIR scores
from three to seven: 3(n=7), 4(n=3), 5(n=5), 6(n=5), 7(n=12) and the mean is 5.38. Here, we had
17 cases in strong positive, 8 cases in pattern in moderate positive and 7 cases in weak postive.
Summary of HOTAIR stain is listed in Table 7. However, the score assigned by software ranged
more broadly, from 0.25 to 17.1 with a mean of 2.34. Figure 15 shows different HOTAIR
expression levels in terms of eye based scoring criteria and their corresponding RNAscope
SpotStudioTM results.
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Table 7. Summary of HOTAIR stain
Tissue

n

mean stain grade

NA
DCIS
IC

26
25
32

3.42
5.04
5.38

Four tiered pattern
Neg W M S
0
23 3
0
0
4 12 9
0
7
8 17

Dichotomous system
Low
High
23
3
4
21
7
25

Neg= negative; W=weak positive; M=moderate positive; S=strong positive

A

20µm
10µm

In this DCIS spot, HOTAIR signal was considered moderate to high intensity, with more than three copies
per cell in more than 75% epithelia cells. Images were taken in 10X objective lens (left) [scale bar: 20 µm]
and 20X lens (right) [scale bar: 10 µm] for same region.

10µm

20µm

This set of images show results of case shown above, analyzed by RNAscope® SpotStudio TM software
package. Green lined cells represent cells which were estimated by software to have more than three copies
of RNA per cell, while blue circled cells displays cells which have less than three copies per cell. However,
black circled cells were unwanted cells which have been eliminated manually. Yellow dot represents single
copy of HOTAIR, and blue shows HOTAIR clusters. In this case, 3526 epithelia cells were selected to have
an estimated 8.32 HOTAIR copies per cell. Images were taken in 10X objective lens (left) [scale bar: 20
µm] and 20X lens (right) [scale bar: 10 µm] for same region.
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B

10µm

20µm

In this normal ajacent tissue spot, HOTAIR signal was recorded low to moderate intensity, with less than
three copies per cell in about 10-50% epithelia cells. Both left images were taken with 10X objective [scale
bar: 20 µm] and right images were same regions as left, taken by 20X microscope lens[scale bar: 10 µm]

10µm

20µm

In this case, RNAscope® SpotStudioTM software was used to analyzed 951 epithelia cells. The overall
estimated HOTAIR copies per cell was 0.82. Images were taken in 10X objective lens (left) [scale bar: 20
µm] and 20X lens (right) [scale bar: 10 µm] for same region

Figure 15. The expression patterns of HOTAIR by CISH
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H19

H19 was stained mostly in the stromal component around breast ducts with some possibilities of
epithelia cell stain as concentrated dots. Within TMAs probe with H19, 40 adjacent tissue spots
including normal adjacent epithelia cells and other normal spaces, 25 DCIS tissue spots and 35
invasive cancer tissue spots were scored by eye. To compare H19 expression between different
tissue types within same individuals, patients who had no less than two different tissue types were
sorted out. For H19, 19 patients kept all three tissue spots, 23 patients had both NA and DCIS
tissue spots, 33 patients had both NA and invasive tissue spots and 20 individuals owned DCIS
and invasive cancer regions. In NA tissue regions, H19 was scored from 0 to 3: 0(n=22), 1(n=1),
2(n=14), 3(n=3) with a median of 0.95, and the 22 of them was recorded as negative and 15 cases
were weak positive and 3 cases were in moderate positive category. In DCIS spots, fewer cases
(n=9) were scored as 0. More cases were assigned to a higher score: 2(n=8), 3(n=3), 4(n=3),
5(n=2). The mean score of H19 in DCIS was 1.88. In terms of pattern distribution, 8 cases were
negative; 9 cases were weak positive; 6 cases were pattern moderate positive and last 2 cases fit
in strong positive group. In invasive cancer spots, H19 expressed broader: 0(n=4), 2(n=1),
3(n=4), 4(n=10), 5(n=7), 6(n=9) and the mean value was 4.08. Here, we had 16 cases in strong
positive, 14 cases in moderate positive, 1 case in weak positive and 4 were negative. We
summarized H19 stain in Table 8. Figure 16 shows different H19 expression levels in terms of
different scoring criteria.
Table 8. Summary of H19 stain
Tissue

n

mean stain grade

NA
DCIS
IC

40
25
35

0.95
1.88
4.08

Three tiered system
Neg W M S
22
15 3
0
9
8
6
2
4
1 14 16

Two tiered system
Low
High
37
3
17
8
5
30

Neg= negative; W=weak positive; M=moderate positive; S=strong positive
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A

20µm

This image represents H19 negative in NA tissue [scale bar: 20 µm]

B

10µm
20µm

Image shows H19 staining mainly in dots of low intensity in one NA tissue. Images were taken in 10X
objective lens (left) [scale bar: 20 µm] and 20X lens (right) for same regions [scale bar: 10 µm]

C

20µm

10µm

H19 singal was detected in patch pattern with a moderate stain intensity in this DCIS spot. Images were
taken in 10X objective lens (left) [scale bar: 20 µm] and 20X lens (right) for same case [scale bar: 10 µm]

63

D

20µm

10µm

In this invasive cancer spot, H19 signal was diffusely found in strong intensity. Images were taken in 10X
objective lens (left) [scale bar: 20 µm] and 20X lens (right) for same region [scale bar: 10 µm]

Figure 16. Expression illustrations of H19 by CISH



KCNQ1OT1

Similar to staining pattern of HOTAIR, KCNQ1OT1 was mostly found in cancer epithelia cell
nuclear as punctate dots in all kinds of tissue. Within TMAs probed with KCNQ1OT1, 30 NA
cell spots, 25 DCIS spots and 32 invasive cancer spots were scored by both eye and RNAscope®
SpotStudioTM software. 10 individuals who kept all three types of tissue, 17 individuals who had
both NA and DICS tissues, 21 patients who had both NA and invasive cancer tissues and 16
patients who had DCIS and invasive cancer tissues were sorted out for further tests. Regarding to
KCNQ1OT1 scores and pattern, all tissue types were assigned a broad range of score. For NA
spots, scores were from 0 to 6: 0(n=5), 2(n=7), 3(n=13), 4(n=1), 5(n=3), 6(n=1) with a mean of
2.6. To fit in our four tiered score system, 5 were negative, 20 cases were in weak positive, 4
cases were moderate positive and 1 strong positive. By software, KCNQ1OT1 scores varied from
0 to 1.73 with a mean of 0.45. In DCIS, we had KCNQ1OT1 score from 0 to 7 (mean=3.76):
0(n=1), 2(n=3), 3(n=8), 4(n=5), 5(n=5), 6(n=2), 7(n=1). In terms of pattern in DCIS, weak
positive (n=11) and moderate positive (n=10) had more number than negative (n=1) and strong
positive (n=3). However, score given by software was narrower, from 0 to 3.46 with a mean of
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0.86. In invasive cancer spots, visual score range was from 2 to 7 (mean=4.4): 2(n=4), 3(n=7),
4(n=5), 5(n=8), 6(n=4), 7(n=4). 11 of them were weak positive, 12 were in moderate positive and
9 were in strong positive group. List of KCNQ1OT1 summary is shown below in Table 9.
RNAscope® SpotStudioTM assigned lower scores than eye (mean=0.97): the minimum was 0.06
and the maximum was 4.95. Figure 17 shows different KCNQ1OT1 expression levels in terms of
eye based scoring criteria and their corresponding RNAscope® SpotStudioTM results

Table 9. Summary of KCNQ1OT1 stain
Tissue
NA
DCIS
IC

n

mean stain grade

30
25
32

2.60
3.76
4.40

Four tiered system
Neg W M
S
5
20 4
1
1
11 10 3
0
11 12 9

Two tiered system
Low
High
25
5
12
13
11
21

Neg= negative; W=weak positive; M=moderate positive; S=strong positive
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A

20µm

KCNQ1OT1 negative in invasive breast tissue [scale bar: 20 µm]

B

20µm

10µm

In this NA tissue, KCNQ1OT1 was stained as punctate dots in low to moderate intensity, with a one to two
copies per cell in less than 10% epithelia cells. Images were taken in 10X objective lens (left) [scale bar: 20
µm] and 20X lens (right) for same region [scale bar: 10 µm]

20µm

1 0µm

The results generated by RNAscope® SpotStudioTM software package for above case were shown here .
Green lined cells represent cells which were estimated by software to have more than two copies of
KCNQ1OT1 RNA per cell, while blue circled cells displays cells which have less than two copies per cell.
However, black circled cells were unwanted cells which have been eliminated manually. Yellow dot
represents single copy of KCNQ1OT1, and blue shows KCNQ1OT1 clusters. In this case, 753 epithelia
cells were selected, which turned out to have an overall estimated 0.35 copies of KCNQ1OT1 per cell.
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C

20µm

10µm

In this invasive breast cancer case, KCNQ1OT1 was stained as punctate singals in moderate to high
intensity, with more than two copies per cell in less about 50-75% epithelia cells. Images were taken in
10X objective lens (left) [scale bar: 20 µm] and 20X lens (right) for same region [scale bar: 10 µm]

20µm

10µm

Here, In this case, RNAscope® SpotStudioTM software was used to analyze 1165 selected epithelia cells to
have an overall estimated 1.83 copies of KCNQ1OT1 per cell. Images were taken in 10X objective lens
(left) [scale bar: 20 µm] and 20X lens (right) for same region [scale bar: 10 µm]

Figure 17. CISH stain of KCNQ1OT1


MEG3

Similar to staining pattern of H19, MEG3 mainly localized in stromal cells around epithelia ducts
as nuclear punctuate stain. 4/91(4%) cases with minor staining in epithelia cells were excluded in
our study. Within TMAs probed with MEG3, 34 NA tissue spots, 23 DCIS tissue spots and 34
invasive cancer spots were scored by eye by pathologist (DL). In MEG3, there were 14 patients
having all three tissue types, 19 patients having NA and DICS tissues, 27 patients having NA and
invasive cancer tissues and 18 cases keeping DCIS and invasive cancer tissues. The mean value
of MEG3 score in NA tissue spots is 1.76 and the range was from 0 to 6: 0(n=21), 2(n=2), 3(n=3),
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4(n=3), 5(n=1), 6(n=5). 21 cases with a score of zero were regarded as negative and from weak
positive to strong positive, we had 2, 6 and 6 cases, respectively. In DCIS, we had fewer cases in
each score (mean=1.3) and pattern: 0(n=14), 2(n=3), 3(n=2), 4(n=3), 6(n=1); negative (n=14),
weak positive (n=3), moderate positive (n=5), strong positive (n=1). Among 34 cases of invasive
cancer spots, 10 were scored 0 and regarded as negative; 2 were scored 2 and grouped as weak
positive; 17 were scored 3 (n=4) or 4 (n=14) and grouped as moderate positive and last 2 cases
were strong positive with a score of 5. The mean score of MEG3 in invasive spots was 1.7. Table
10 shows MEG3 stain summary and figure 18 shows different MEG3 expression levels in terms
of different scoring criteria.
Table 10. Summary of MEG3 stain
Tissue
NA
DCIS
IC

N

mean stain grade
34
23
34

1.76
1.30
1.7

Four tiered system
Neg W
M S
21
2
6
6
14
3
5
1
10
2
17
2

Two tiered system
Low
High
21
14
14
9
10
21

Neg= negative; W=weak positive; M=moderate positive; S=strong positive
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A

20µm

Negative stain of MEG3 on one NA breast case, image was taken with 10X objective lens
[scale bar: 20 µm]

B

20µm

10µm

Here, MEG3 was stained in moderate intensity in more than 75% stromal cells in invasive cancer spot.
Images were taken in 10X objective lens (left) [scale bar: 20 µm] and 20X lens (right) for same region
[scale bar: 10 µm]
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C

10µm

20µm

(C) shows that MEG3 was detected in 50-75% stromal cells, mainly in low stain intensity in DCIS. Images
were taken in 10X objective lens (left) [scale bar: 20 µm] and 20X lens (right) for same region [scale bar:
10 µm]

D

20µm

10µm

Images represent strong stain of MEG3 in more than 75% stromal cells in benign breast tissue. Images
were taken in 10X objective lens (left) [scale bar: 20 µm] and 20X lens (right) for same region [scale bar:
10 µm]

Figure 18. Stain illustrations of MEG3
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MALAT1

MALAT1 was extensively and intensively stained in each cell across three different tissues. We
were unable to show any stain difference in MALAT1 and thus we were unable to test any
statistical significance between groups. Figure 19 illustrates the generic staining pattern of
MALAT1.

B

A

20µm

20µm

C

20µm

MALAT1 was universally strongly stained on NA tissue (A), DCIS (B) and invasive cancer tissue (C). All
images were photographed with 10X objective lens. [scale bar: 20 µm]

Figure 19. Strong positive stain of MALAT1
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Zfas1

Zfas1 stained like HOTAIR and KCNQ1OT1, which were punctate dots in epithelia cell nucleus.
Although we saw some minor difference in stain proportion, the overall staining intensity was
every low and overall score of cases were very close. So, we were unable to perform statistical
analysis to demonstrate any significance in Zfas1. Figure 20 illustrates the generic staining
pattern of Zfas1.

B

A

10µm

10µm

C

10µm

Zfas1 was hardly seen in NA tissue (A); DCIS (B) and invasive cancer tissue(C). All images were taken
with 20X objective lens. [scale bar: 10 µm]

Figure 20. Faint stain of Zfas1 across TMAs
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Long non-coding RNA associated protein staining results
 EZH2
Staining in epithelia cell nucleus, EZH2 was more prevalent in cancer cells rather than normal
adjacent epithelia cells. Across our TMAs, we gave EZH2 score for 28 NA spots, 21 DCIS spots
and 31 invasive spots. Among all patients, 10 individuals had all three tissue types available; 16
individuals had both NA and DCIS spots; 16 individuals kept both NA and invasive cancer spots;
15 individuals had DCIS and invasive cancer spots. In NA spots, most of cases (23/28) were
scored as 0 and two cases were 1 and one case was 2, 3, and 4, respectively. Thus, we had
negative pattern (n=23), weak positive (n=2) and moderate positive (n=2). In DCIS regions, 9
cases were scored of zero and we had more score distributions: 1(n=2), 2(n=7), 4(n=1), 6(n=2). In
regard to pattern, nine cases were grouped as negative, another nine cases were in weak positive,
one case was in moderate positive and rest two cases were in strong positive. However, in
invasive cancer spots, we had 15 cases as EZH2 negative while other scores include 1(n=4),
2(n=4), 3(n=1), 4(n=3), 5(n=2), 6(n=2). Eight of them were in weak positive, four in moderate
positive and three in strong positive. A summary of EZH2 stain is listed in Table 11. Figure 21
shows different EZH2 expression levels according to different scoring criteria.
Table 11. Summary of EZH2
Tissue

N

mean stain
grade

NA
DCIS
IC

28
21
31

0.39
1.57
1.58

Four tiered system
Neg
23
9
15
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W
2
9
8

M
3
1
4

S
0
2
3

Dichotomous scoring
system
Low
High
25
3
11
10
19
12

A

B

20µm

20µm

C

D

20µm
20µm

Figure 21. Different expressions of EZH2 across samples (A) Negative case of EZH2 in normal adjacent breast tissue; (B) EZH2 was found less than 10% epithelia cells
with low stain intensity in benign breast tissue ;(C) EZH2 appeared in 50-75% epithelia cells in moderate intensity in invasive cancer; (D) Image shows EZH2 strong
stain in more than 75% epithelia cells in DCIS (all images were taken with 10X lens) [scale bar: 20 µm]
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CDKN1C/p57

CDKN1C was widely (>50%) and strongly stained in nucleus including epithelia, glandular and
adipocyte cell nucleus in any NA spots and cancer spots, like what we found from MALAT1.
Therefore, we were unable to show any statistical difference between each tissue type. Here,
Figure 22 illustrates the generic staining format of CDKN1C.

20µm

Figure 22. CDKN1C generic stain
CDKN1C extensively expressed in nucleus with high intensity. Image was photographed with 10X lens
[scale bar: 20 µm]



P53

Unlike CDKN1C, p53 was hardly stained in our TMAs. No p53 was found across all NA tissue
spots. In our cancer spots, we found 10% (2/20) positive cases in DCIS and 6.3% (2/32) positive
cases in invasive cancer. All positive cases had nuclear stain of p53, however, only one case
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showing cytoplasmic staining was excluded in our study. Both p53-positive and p53-negative
cases are displayed in Figure 23.

A

B

20µm
20µm

Figure 23. Positive and negative illustrations of p53
(A) p53 positive in invasive cancer (B) p53 negative in NA breast, all images are in 10X objective lens
[scale bar: 20 µm]

Clinicopathological factors staining results
Basic clinicpathological data was obtained from patient records. In our study, we confirmed ER,
PR and Her2 status, explored Ki67 (MIB1) and E-cadherin status by doing
immunohistochemistry on our TMAs.


Estrogen Receptor

We dichotomized ER status in DCIS and invasive cancer spots. In DCIS regions, ER positive
were found in 26/30 cases and the rest was all ER negative. In invasive cancer tissue, we had
40/44 cases were ER positive and 4/44 were ER negative, which is in concord with the original
patients information. ER staining illustrations are shown in Figure 24.
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A

B

20µm
20µm

Figure 24. Positive and negative illustrations of ER
(A) ER negative (B) ER positive; Images were taken in 10X objective lens [scale bar: 20 µm]



Progesterone receptor(PR)

PR status was tested in DCIS and invasive cancer tissues. 24 cases were found PR positive and 6
cases were found PR negative in DCIS spots, while 36 spots were PR positive and 8 spots were
PR negative in invasive cancer. Data collected from TMA staining perfectly matched previous
clinical information. PR staining examples are shown in Figure 25. Hormone receptor statues
were 26/30 positive in DCIS and 40/44 positive in invasive cancer.

B

A

20µm

20µm

Figure 25. Positive and negative illustrations of PR
(A) PR negative (B) PR positive; Images were taken in 10X objective lens [scale bar: 20 µm]

77



Her2

Her2 protein stained the membrane by IHC. In DCIS, there were no equivocal cases among all 16
spots that was scored: 0(n=8), 1(n=5), 3(n=3), so only 3 cases were recorded as Her2 positive. In
invasive spots, we scored 0 for 22 cases, 1 for 6 cases, 2 for 2 cases and 2 for 3 cases. After
reconfirmation by dual in situ hybridization (one centromerical probe for chromosome 17 and
one Her2 probe, performed in the FAHC lab), those 2 equivocal cases were grouped as Her2
positive. In conclusion, 28 cases were Her2 negative and 4 were Her2 positive. Due to TMA
construction issue, we missed several spots in our TMAs, resulting in fewer Her2 statues than
original patient data, however, since all current TMA Her2 statues perfectly concords with
original Her2 statues, we made up those missing data from original Her2 statue, resulting in an
overall Her2 positive of 5 cases and Her2 negative of 38 cases. Figure 26 shows Her2 staining
examples. (All images were photographed with 10x objective lens except dual CISH)
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A

B

C

20µm

20µm
20µm

D

F

20µm

10µm

Figure 26. Examples of Her2 stain
(A) Image shows Her2 negative case with a score of zero (B) image represents Her2 negative case with a score of one (C) Her2 positive with a score of
three (D) Her2 equivocal case with a score of two by immunohistochemistry (E) Dual color CISH confirmed overexpression of Her2 in equivocal case.
Image was taken with 10x objective lens in (A-D) [scale bar: 20 µm] and 20x objective lens (F) [scale bar: 20 µm]
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Ki67 (MIB1)

Ki67 protein was stained mostly as single or multiple dots, sometimes in clusters in epithelia cells.
In DCIS spots, Ki67 protein was scored as 1(n=3), 2(n=5), 3(n=4), 4(n=6) based on percentage of
cells that were stained. So, only those six cases with a score of 4 were recorded as Ki67 positive.
In invasive cases, we found more Ki67 positive case with a score of 4 (13/35). Among the other
22 cases which are Ki67 negative, 8 were scored 1, 10 were 2 and 4 were 3. Staining illustrations
are shown in Figure 27.

A

B

20µm
20µm

Figure 27. Illustrations of ki67 status
(A) shows Ki67 negative because it only expressed in 5% cells (less than 15% threshold) (B)
represents Ki67 positive case [scale bar: 20 µm]
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E-Cadherin

E-cadherin was only stained in ductal carcinoma in situ or invasive ductal carcinoma, but
negative in lobular carcinoma, shown in Figure.28.

20µm

Figure 28. E-cadherin positive in invasive ductal carcinoma case [scale bar: 20 µm]

Statistical analysis
 Correlations between two independent scoring systems
In order to demonstrate the data consistency between eye-based scoring system and RNAscope®
SpotStudioTM scoring software we used in for two lncRNA makers, HOTAIR and KCNQ1OT1,
we used non-parametric Spearman rank correlation test to check the correlations (Table.12a and
12b). In HOTAIR, significant correlations between two systems were found in DCIS and invasive
cancer subjects, while correlations were shown in all three tissue types in KCNQ1OT1.
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Table 12. Spearman correlation study between two scoring systems
a. Spearman correlation test for HOTAIR in all three tissue types
Tissue type
NA
DCIS
IC

Spearman’s rho
0.339
0.497
0.716

Sample size (n)
26
25
32

Probabilities
0.067
<0.001
<0.0001

b. Spearman correlation test for KCNQ1OT1 in all three tissue types
Tissue type
NA
DCIS
IC



Spearman’s rho
0.749
0.681
0.769

Sample size (n)
30
25
32

Probabilities
<0.0001
<0.0001
<0.0001

Comparison of lncRNA expression across tissues

To test our hypothesis that lncRNAs may express differently across tissue types, we applied nonparametric Friedman two-way analysis of variance test on subjects containing all three tissue
types. From the perspective of eye scoring system, HOTAIR, H19 and KCNQ1OT1 expressions
are significantly different across tissues. KCNQ1OT1 also has expression difference across our
samples, while HOTAIR seems to have equal expression in different tissues in terms of score that
produced by RNAscope® software (Table.13). Further paired comparison by same Friedman
tests were applied only after overall tests was significant, resulting in more details upon different
variables: the eye-determined expression levels of HOTAIR and H19 differs significantly in each
paired comparison (Table.14a, Table.14b), however, both eye-determined and software
determined KCNQ1OT1 score varies between normal adjacent and cancer, but not non-invasive
and invasive (Table.14c).
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Table 13. Non-parametric comparison for lncRNAs expression across tissues
lncRNA variable

NA tissue rank
sum

DCIS tissue
rank sum

Invasive cancer
rank sum

Sample size
(n)

Friedman
Test Statistic

P value

HOTAIR score
HOTAIR pattern
HOTAIR software

13.5
13.5
17.5

23.5
23.5
21.0

29.0
29.0
27.5

11
11
11

15.9
15.9
4.9

<0.001
<0.001
0.086

H19 score
H19 pattern

27.0
27.5

34.5
34.0

52.5
52.5

19
19

25.0
25.4

<0.001
<0.001

KCNQ1OT1
score
KCNQ1OT1
pattern
KCNQ1OT1
software

11.5

22.0

26.5

10

13.5

0.001

13.0

22.5

24.5

10

10.4

0.005

12.0

23.0

25.0

10

9.8

0.007

MEG3 score
24.5
28.0
31.5
14
4.5
0.108
MEG3 pattern
25.0
28.0
31.0
14
3.4
0.180
Score represents the score was given by standard visual evaluation; pattern means the score was given by four tiered scoring system; software indicates
the score was given by RNAscope® sotware
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Table 14. Non-parametric paired comparisons for lncRNAs
a.Non-parametric paired comparison for HOTAIR

lncRNA variable
HOTAIR score

HOTAIR pattern

NA tissue rank
sum
30.5
34.5
/

DCIS tissue
rank sum
38.5
/
23.0

Invasive cancer
rank sum
/
64.5
37.0

Sample size
(n)
23
33
20

Friedman Test
Statistics
5.3
30.0
12.3

P value

30.5
35.0
/

38.5
/
23.0

/
64.0
37.0

23
33
20

5.3
29.0
14.0

0.021
<0.001
<0.001

0.021
<0.001
<0.001

b. Non-parametric paired comparison for H19

lncRNA variable
H19 score

H19 pattern

NA tissue rank
sum
17.5
22.5
/

DCIS tissue
rank sum
27.5
/
22.0

Invasive cancer
rank sum
/
37.5
29.0

Sample size
(n)
15
20
17

Friedman Test
Statistics
10.0
15.0
7.0

Probabilities

17.5
22.5
/

27.5
/
22.0

/
37.5
29.0

15
20
17

10.0
15.0
7

0.002
<0.001
0.008
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0.002
<0.001
0.008

c. Non-parametric paired comparison for KCNQ1OT1
lncRNA variable

NA tissue rank
sum
21.0
22.5
/

DCIS tissue
rank sum
30.0
/
21.0

Invasive cancer Sample size
rank sum
(n)
/
17
40.5
21
27.0
16

Friedman Test
Statistics
6.2
16.2
3.6

Probabilities

KCNQ1OT1 pattern

21.5
23.5
/

29.5
/
21.5

/
39.5
26.5

17
21
16

6.4
16.0
2.8

0.011
<0.001
0.096

KCNQ1OT1
software

19.0

32.0

/

17

9.9

0.002

24.0
/

/
24.0

39.0
24.0

21
16

10.7
0

0.001
1

KCNQ1OT1 score
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0.013
<0.001
0.058



Association between lncRNA expressions and DCIS clinical markers

We also tested the hypothesis that lncRNA expression may associate with DCIS clinical markers.
Pearson correlation test was firstly conducted to screen potential correlations (Table 15). Here,
we kept DCIS nuclear grade as initial report, which had five groups from 1 to 3. All potential
correlations were further tested in non-parametric Kruskal-Wallis one-way ANOVA or MannWhitney U test (Table 16a, 16b, 16c), suggesting multiple potential associations in HOTAIR and
H19 were still valid, but most associations determined by Pearson test in KCNQ1OT1 were
incongruent with current methodology. (In Table 16a, 16b, 16c, KW represents Kruskal-Wallis
test that was used for groups > 3, MW indicates Mann-Whitney U test that was used for groups of
2)
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Table 15. Pearson correlation matrix between lncRNA and clinicopathological markers in DCIS
ER
status

PR
Status

Hormone
status

Her2
Status

Ki67
status

P53
Status

HOTAIR score
HOTAIR pattern
HOTAIR software

DCIS
nuclear
grade
/
/
/

/
/
-0.83(<0.001)

/
/
-0.49(0.014)

/
/
-0.83(<0.001)

0.66(0.005)
0.54(0.032)
/

0.50(0.036)
/
0.58(0.011)

/
/
/

H19 score
H19 pattern

/
/

/
/

/
/

/
/

/
/

0.49(0.045)
0.53(0.03)

/
/

KCNQ1OT1 score
KCNQ1OT1 pattern
KCNQ1OT1 software

0.44(0.026)
0.43(0.033)
/

/
/
0.56(0.004)

/
/
/

/
/
0.56(0.004)

/
/
/

0.51(0.029)
0.51(0.029)
0.48(0.044)

/
/
0.54(0.014)

MEG3 score
MEG3 pattern

/
/

/
/

/
/

/
/

/
/

/
/

/
/

Data are given as Pearson correlation coefficient (p value) of each cell. “/” indicates there is no significant association between two variables
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Table 16. Non-parametric Kruskal-Wallis test/ Mann-Whitney U test of lncRNAs in DCIS
a. Non-parametric Kruskal-Wallis test/ Mann-Whitney U test of HOTAIR
Score/Her2
Score/Ki67

sample size(n)
16
18

KW/MW statistics
1.5
15.0

Probabilities
0.013
0.044

Pattern/Her2

16

4.5

0.03

Software/ER
Software/PR
Software/Hormone
Software/Ki67

25
25
25
18

46.0
47.0
46.0
7.0

0.021
0.711
0.021
0.007

b. Non-parametric Kruskal-Wallis test/ Mann-Whitney U test for H19
Sample Size(n)
17
17

Score/Ki67
Pattern/Ki67

KW/MW statistics
14.0
14.5

Probabilities
0.045
0.047

c. Non-parametric Kruskal-Wallis test/ Mann-Whitney U test for KCNQ1OT1
Score/DCIS grade
Score/Ki67

Sample size (n)
25
18

KW/MW statistics
7.0
15.5

Probabilities
0.072
0.043

Pattern/DCIS grade
Pattern/Ki67

25
18

7.4
18.0

0.06
0.052

Software/ER
Software/Hormone
Software/Ki67
Software/p53

25
25
18
20

39.0
39.0
17.0
11.0

0.109
0.109
0.075
0.38
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Besides non-parametric Kruskal-Wallis one-way ANOVA or Mann-Whitney U test that shows
some associations between lncRNA expression level and DCIS clinical markers according to
statistical difference in mean, we also applied Fisher’s exact test to demonstrate associations
between lncRNA expression and clinical markers in terms of different frequency. Here, we
performed all tests on dichotomized number for both lncRNA expression level and clinical
markers in order to provide us with more significant correlations and more understandable
interpretations based on our sample size. All the fisher’s exact tests were done by 2x2
contingency table. (Table 17)

Table 17. Association study between dichotomous lncRNA level and clinical markers in DCIS by
Fisher’s exact test
Clinical item
DCIS grade

ER

PR

Her2

Ki67

P53

lncRNA
HOTAIR
H19
KCNQ1OT1
MEG3
HOTAIR
H19
KCNQ1OT1
MEG3
HOTAIR
H19
KCNQ1OT1
MEG3
HOTAIR
H19
KCNQ1OT1
MEG3
HOTAIR
H19
KCNQ1OT1
MEG3
HOTAIR
H19
KCNQ1OT1
MEG3

Sample size
25
25
25
23
25
25
25
23
25
25
25
23
16
15
16
16
18
17
18
18
20
19
20
20

Fisher’s exact test value
0.294
0.661
0.294
0.657
1.00
0.507
1.00
0.142
0.527
0.140
1.00
1.00
1.00
1.00
1.00
1.00
0.515
0.280
0.515
0.620
1.00
1.00
1.00
0.189
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Odds Ratio
∞
0.476
∞
0.514
0
∞
0
0
2.00
∞
0
0.583
∞
1.50
∞
2.333
∞
4.50
∞
2.80
∞
2.40
∞
∞



Association between lncRNA expressions and invasive clinical markers

Subsequently, we applied same working procedures to determine the hypothesis that lncRNA
expression may associate with invasive clinical markers. Pearson correlation test was firstly used
as screen tool (Table 18) and non-parametric Kruskal-Wallis one-way ANOVA or MannWhitney U test were applied to validate candidate associations (Table 19a, 19b, 19c). In this test,
Nottingham score remained from 4 to 9 and tumor size were trichotomized. (In table 10a, 10b,
10c, KW represents Kruskal-Wallis test that was used for groups > 3, MW indicates MannWhitney U test that was used for groups of 2)
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Table 18. Pearson correlation matrix in invasive cancer
Nottingham
grade

Tumor
size

LVI
status

ER
status

PR
status

Hormone
status

Triple
negative

Her2
status

Ki67
Status

P53
status

HOTAIR score

0.35(0.049)

0.40(0.023)

/

/

/

/

/

/

0.4(0.04)

/

HOTAIR pattern
HOTAIR software

0.37(0.037)
0.35(0.050)

0.40(0.023)
0.37(0.036)

/
/

/
-0.53(0.002)

/
/

/
-0.53(0.002)

/
0.53(0.002)

0.37(0.039)
0.07(0.001)

0.37(0.041)
/

/
/

/
/

/
/

/
/

H19 score

/

/

/

/

/

/

/

H19 pattern

/

/

/

/

/

/

/

/
/

/
/

/
/

KCNQ1OT1 score

0.41(0.02)

/

/

/

/

/

/

/

/

/

KCNQ1OT1 pattern
KCNQ1OT1 software

0.51(0.003)
0.54(0.008)

/
/

/
/

/
0.81(<0.001)

-0.36(0.042)
0.70(<0.001)

/
0.81(<0.001)

/
/

0.39(0.027)
/

/
/

/
/

MEG3 score

/

/

/

/

/

/

/

/
/

/
/

/
/

MEG3 pattern

/

/

/

/

/

/

/

0.38(0.027)

/

/

Data are given as Pearson correlation coefficient (p value) of each cell. “/” indicates there is no significant association between two variables
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Table 19. Non-parametric Kruskal-Wallis test/ Mann-Whitney U test of lncRNAs in invasive
cancer
a. Non-parametric Kruskal-Wallis test/ Mann-Whitney U test of HOTAIR

Score/Nottingham
Score/tumor size
Score/Ki67 status

sample size(n)
32
32
31

KW/MW statistics
6.9
5.1
58.5

Probabilities
0.231
0.077
0.019

Pattern/Nottingham
Pattern/tumor size
Pattern/Her2
Pattern/Ki67

32
32
32
31

7.1
5.1
30.0
67.5

0.215
0.078
0.032
0.039

Software/Nottingham
Software/tumor size
Software/ER
Software/hormone
Software/triple N
Software/Her2

32
32
32
32
32
32

4.9
4.4
31.0
60.0
29.0
13.0

0.431
0.112
0.938
0.019
0.938
0.005

b. non-parametric Kruskal-Wallis test/ Mann-Whitney U test for KCNQ1OT1

Score/Nottingham

sample size(n)
32

KW/MW statistics
6.4

Probabilities
0.267

Pattern/Nottingham
Pattern/PR
Pattern/Her2

32
32
32

10.2
103.0
20.5

0.071
0.05
0.032

Software/Nottingham
Software/ER
Software/PR
Software/hormone

32
32
32
32

5.0
60.0
125.5
60.0

0.415
0.019
0.003
0.019

c. non-parametric Kruskal-Wallis test/ Mann-Whitney U test for MEG3

Pattern/Her2

sample size (n)
34

KW/MW statistics
30.5
92

P
0.026

Similarly, we test whether lncRNAs are associated with clinical makers regarding frequency by
using Fisher’s exact test. We also performed all tests on dichotomized number for both lncRNA
expression level and clinical markers except invasive histological grade, which was analyzed
non-parametric spearman rank correlation test. All the fisher’s exact tests were done by Pearson
Chi-Square 2x2 contingency table (Table 20), and spearman rank study was tested in 2x3 table
(Table 21).
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Table 20. Association study between dichotomized lncRNA level and clinical markers in invasive
cancer by Fisher’s exact test
clinical items

lncRNA

sample size

Tumor size

HOTAIR
H19
KCNQ1OT1
MEG3
HOTAIR
H19
KCNQ1OT1
MEG3
HOTAIR
H19
KCNQ1OT1
MEG3
HOTAIR
H19
KCNQ1OT1
MEG3
HOTAIR
H19
KCNQ1OT1
MEG3
HOTAIR
H19
KCNQ1OT1
MEG3
HOTAIR
H19
KCNQ1OT1
MEG3
HOTAIR
H19
KCNQ1OT1
MEG3
HOTAIR
H19
KCNQ1OT1
MEG3

32
35
32
34
28
31
28
29
32
35
32
34
32
35
32
34
32
35
32
34
32
35
32
34
32
35
32
34
31
34
31
32
31
32
30
32

Lymph node

LVI

ER

PR

Triple negative

Her2

Ki67

P53

Fisher’s exact test
value
0.069
0.297
0.550
0.683
0.128
0.147
0.295
0.107
0.025
0.630
0.272
0.251
1.000
0.477
1.000
1.000
1.000
0.568
1.000
0.644
1.000
0.477
1.000
1.000
0.560
1.000
1.000
0.291
0.201
1.000
0.601
1.000
0.406
1.000
1.000
1.000

Fisher’s exact statistics are two-tailed
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Odd ratio
∞
∞
∞
2.00
∞
∞
∞
6.55
∞
2.667
∞
3.385
0
2.250
0
0
.667
2.667
0
0.422
∞
0.444
∞
∞
∞
∞
∞
∞
5.077
2.000
0.500
1.286
0.261
∞
∞
∞

Table 21. Association study between dichotomized lncRNA level and invasive histological grade
in invasive cancer by Spearman rank correlation test
Clinical item
Histological grade

lncRNA
HOTAIR
H19
KCNQ1OT1
MEG3

sample size
32
35
32
34

Spearman Rho
0.375
0.090
0.071
0.168

Probabilities
0.026
0.583
0.719
0.271

Probabilities are two-tailed



Logistic regression analysis for lncRNA to predict cancer aggressiveness

As we already noticed some associations between lncRNA expression level and clinical markers
by either Kruskal-Wallis one-way ANOVA test or Fisher’s exact test, we subsequently tested the
hypothesis that lncRNAs combined clinical items status can better predict DCIS or invasive
cancer grade. First of all, we used Fisher’s exact test on dichotomized dataset to look for
associations between DCIS nuclear grade and all other markers (Table 22a), and we also applied
Spearman rank correlation study to check any correlation between trichotomized invasive
histological grade and the other markers (Table 22b). From our analysis, we did not find any
significant correlation between DCIS nuclear grade and lncRNAs, but ER (p=0.012). However,
since there was only one variable suggesting association, we did not perform multivariate test. In
invasive cancer subjects, multiple variables have been found correlation with histological grade,
including HOTAIR (p=0.026), ER (p<0.001, negative relationship), triple negative (p<0.001) and
Ki67 (p<0.001). Then we provided multivariate logistic regression to test the predictability of
cancer grade by a set of predictor variables.
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Table 22. Correlation test of cancer grade and all markers
a. Correlation test for DCIS nuclear grade by Fisher’s exact test
Variable 1
DCIS nuclear grade

Variable 2
HOTAIR
H19
KCNQ1OT1
MEG3
ER
PR
Her2
Ki67
P53

Sample size
25
25
25
23
30
30
16
18
20

Fisher’s exact test value
0.294
0.661
0.294
0.657
0.012
0.156
0.518
0.107
0.521

b. Correlation test for invasive histological grade by Spearman rank correlation test
Variable 1
Invasive histological grade

Variable 2
HOTAIR
H19
KCNQ1OT1
MEG3
Tumor size
Lymph node
LVI
ER
PR
Triple negative
Her2
Ki67
P53

Sample size
32
35
32
34
44
38
44
44
44
44
43
35
33

Probabilities
0.026
0.582
0.719
0.271
0.234
0.517
0.739
<0.001(negative)
0.082
<0.001
0.155
<0.001
0.138

Binary logit analysis was chosen because we dichotomized histological grades as our limited
sample size. Firstly, we categorized invasive histological grade into low grade (n=8) coded with 0
and non-low grade (n=19) coded with 1. We took the first step to consider bivariate logistical
regression, using dichotomized histological grade as criterion variable and lncRNA expression
level as dichotomous predictor variable. Our regression model will be predicting the logit, that is,
the natural log of the odds of having one or the other histological grade (model is shown below),

96

where Y was the probability of the event which is coded with 1, 1-Y was the predicted probability
of the event coded with 0, and X was the predictor variable, lncRNA dichotomized score.

Our data suggests only HOTAIR (p=0.011) was a positive predictor among all lncRNAs and odds
ratio was 14.167. Our regression equation is

.

Then, we applied same binary logit analysis on all dichotomized clinical items. However, it
turned out that no clinical items was a good predictor. Lastly, we performed a multivariate
logistical regression to take both dichotomous lncRNA expression and clinical items into account.
We set up another model to predict odds as shown below, where Y was the probability of the
event which is coded with 1, 1-Y was the predicted probability of the event coded with 0, and Xn
was a single predictor variable, lncRNA or clinical item

Only lymphovascular invasion (LVI) status (p=0.08) and HOTAIR (p=0.043) showed a joint
ability to predict cancer grade with an odds ratio 16.5. Our equation is
, where X1 represents lymphovascular invasion status and X2 represents
HOTAIR.
Similarly, we categorized invasive histological grade into high grade (n=6) coded with1 and nonhigh grade (n=21) coded with 0. However, we could only find Ki67 status is a good predictor
(p=0.013) from binary logit analysis.
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Correlation between protein markers and lncRNA expression

Functionally, one mechanism of lncRNAs influencing gene expression is to recruit epigenetic
protein factors to regulate chromatin states of target gene in cis or trans. Polycomb repressive
complex 2, (PRC2), as a chromatin-modifying complex, interacts with a large group of lncRNA
including HOTAIR, H19 and KCNQ1OT1. From our study, we found EZH2 significantly
expressed higher in cancer than in NA breast tissue (p<0.001) Here, we tested the hypothesis that
the expression of Enhancer of zeste homolog 2 (EZH2), as a key protein member of PRC2
complex as gene silencer, increases as lncRNAs express, by Pearson correlation study (Table 23).
Our data suggests only one correlation between KCNQ1OT1 expression and EZH2 expression in
invasive cancer (p=0.006).
Table 23. Pearson correlation study between protein markers and lncRNA expression
Tissue
NA

Protein
marker
EZH2

DCIS

EZH2

IC

EZH2

lncRNA
HOTAIR
H19
KCNQ1OT1
HOTAIR
H19
KCNQ1OT1
HOTAIR
H19
KCNQ1OT1

Sample
size
23
26
25
21
21
21
29
31
29
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Pearson
correlation
0.034
0.272
-0.007
0.294
0.371
0.065
-0.085
0.016
0.495

Probability
0.877
0.179
0.972
0.197
0.098
0.781
0.662
0.993
0.006

Discussion
RNAscope® in situ hybridization assay
Regarding the work platform, RNAscope in situ hybridization technology has now been
employed elsewhere to detect lncRNA (Bao, Wu et al. 2013 [male mouse germline]; Prensner,
Iyer et al. 2013 [prostate cancer]; Warrick, Tomlins et al. 2014 [prostate cancer]), providing
valuable information on clinical relevant information upon cellular and tissue context that is
unable to visualize by routine microarray and quantitative PCR. The present study demonstrates
the quality and specificity of RNAscope technology to detect lncRNA on FFPE tissues.
Sample size
In current study, tissue microarray was manufactured to provide a standard and high throughput
assays on same tissue source for both RNA candidate markers and immunohistochemical markers
with comparatively low cost. Although routine H&E slides were made from selected FFPE blocks
to help pathologists to mark concurrent developed DCIS, invasive cancer and adjacent normal
tissue regions that would be included in TMAs, mixed tissue areas were accidentally found on our
TMA slides after we rescreened TMA slides with H&E slides for confirmation. In that case, we
only reviewed tissue piece that was intended to be there. As breast tissue contains most abundant
adipocytes, 8 of 44 (18%) normal adjacent spots turned out to only have adipose tissue so that
they were excluded for further analysis. We had the least number of DCIS spots (n=34) across
our TMAs because of two reasons: 1) several patients only had NA and invasive cancer tissues 2)
several spots contained very little DCIS part that was easily removed during manufacturing
process. Comparing with NA and DCIS tissue, we kept the most number (n=44) of invasive
cancer tissue source. However, we ended up having fewer tissue spots on our TMAs to score and
analyze because some more spots were washed away during multiple pretreatment and
amplification steps, even with more cautions, resulting in a limited sample size.

99

HOTAIR
Our results suggest lncRNAs have different staining patterns, mostly in concord with previous
publications. The HOTAIR RNA probe stained predominately as single or multiple dots that was
widely present in all three tissue sources (Chisholm, Wan et al. 2012 [digoxigenin-labeled
riboprobe ISH]). However, most signals were found in nucleus with some scattered dots in
cytoplasm, contrary to what Chisholm, et al. found in their paper, which suggests HOTAIR was
more prevalent in cytoplasm (Chisholm, Wan et al. 2012). As their primary focus on metastatic
breast carcinoma while we were looking at primary tumors, it is possible that HOTAIR escapes
from nucleus to cytoplasm as primary tumor metastases. Our data also provides us some evidence
that HOTAIR expresses at different levels across different types of tissue. Generally HOTAIR
signal enhances as cancer aggressiveness increases. Friedman two-way analysis of variance test
shows HOTAIR has significantly higher expression in cancer cells than normal adjacent epithelia
cells (p<0.001). Even within cancer spots, invasive cancer is more aggressive and has more
intense HOTAIR score than that of DCIS (p=0.021).
KCNQ1OT1
Prior studies have used fluorescent in situ hybridization (FISH) to visualize KCNQ1OT1 signal in
nucleus of both human and mouse cells (Mohammad, Pandey et al. 2008; Korostowski, Sedlak et
al. 2012). This is the first study to localize KCNQ1OT1 as punctuate dots in cell nucleus on FFPE
tissue samples by CISH. Comparing with HOTAIR, KCNQ1OT1 is not that popular in terms of
staining grade. Across our tissue microarray, we have 5 negative cases without any stain of
KCNQ1OT1, most of which (4/5) are normal adjacent tissue spots, suggesting KCNQ1OT1 may
express more frequently in cancer spots as a candidate oncogene. Also, there is an increased
KCNQ1OT1 expression in regard to KCNQ1OT score in cancers than in NA (p=0.013). However,
we did not notice any statistical difference of KCNQ1OT1 expression between non-invasive
DCIS tissue and more malignant invasive cancer spots (p=0.058), revealing some possibilities
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that KCNQ1OT1 is triggered by some pre-cancer events and then keep expressing as cancer
develops.
H19
As an important oncogene for tumor growth, H19 was first detected in hepatocellular carcinoma
by both radioactive and non-radioactive riboprobe in situ hybridization (Ariel, Miao et al. 1998).
The present study provides some insights to localize H19 in breast carcinoma by RNAscope
CISH. H19 was stained more diffusely and intense in cancer, compared with normal adjacet spots
that usually negative or focal expression (p<0.001), strikingly, H19 also expressed significantly
higher in more malignant invasive cancer than in DCIS (p=0.008). In this study, we also found
that H19 appeared primarily in stromal cells of breast tissue especially at the boundary of breast
cancer ducts as also reported by Ariel and his colleagues in 1998. However, other studies have
also found H19 stained in epithelia ovarian cancer cells and bladder cancer cells (Mizrahi,
Czerniak et al. 2009; Amit and Hochberg 2010). Together with current research focus on exsomes
guided tumorigenesis and the fact lncRNAs has been found in exosomes by deep sequencing
(Huang, Yuan et al. 2013), it may give rise to additional research to investigate H19 and tumor
microenvironment.
MEG3
Similar to H19, our image depicts that MEG3 stained in stromal cell nucleus around breast ducts,
which is the first study to visualize MEG3 RNA molecule on breast tissue. Our results compared
MEG expression in each tissue types and found there was no significance between tissue types
(p=0.108), while previous study showed MEG3 was lost in human breast cancer cell line MCF-7
and thus proposed MEG3 might be a novel tumor suppressor (Zhang, Zhou et al. 2003). This
contradiction may be because of much more complexity and chaos in real human tissue than pure
cell line, which would turn out to have different conclusions. Other than staining stromal cells,
MEG3 has also been found previously to localize in most normal pituitary cells (Gejman, Batista
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et al. 2008) and in cytoplasm of non-neoplastic liver cells(Braconi, Kogure et al. 2011), indicating
MEG3 might be involved in a spectrum of cell activity with different functionalities.
MALAT1
As a key regulator in lung cancer, MALAT1 was implicated to play an oncogenic role and
upregulation of MALAT1 was also observed in several other cancers, including breast cancer
(Lin, Maeda et al. 2007). On the contrary, our results exhibited a universal strong nuclear stain of
MALAT1 for every tissue spots of our tissue microarray slides. However, the reason that results
in contradictory results is largely unknown, leading us to investigate both expressional and
functional perspectives of MALAT1 in breast cancer in more details.
Zfas1
One Snord-host long noncoding RNA Zfas1, has been suggested detected by chromogenic in situ
hybridization in mice pregnant mammary gland epithelia cells and the paper also evidenced that
Zfas1 might be a breast cancer tumor suppressor by showing relatively lower expression level of
Zfas1 in human breast cancer than in normal by quantitative PCR (Askarian-Amiri, Crawford et
al. 2011). Current study on Zfas1 depicted a similar Zfas1 staining pattern as previous study
showed, both of which were stained as low intensity dots in epithelia cell nucleus. Nonetheless, in
order to assign them scores, even experienced pathologists had trouble to tell the minor difference
between subjects so we did not review Zfas1 as carefully as other lncRNAs in order to prevent
scoring bias. In situ hybridization assay, together with quantitative PCR or advanced quantitative
image software, would be the best choice to further analyze Zfas1.
LncRNA and EZH2
EZH2, a key subunit of polycomb repressive complex 2 that is usually interacts with lncRNA, has
been extensively associated with lncRNA, especially HOTAIR, H19 and KCNQ1OT1(Gupta,
Shah et al. 2010; Luo, Li et al. 2013; Zhang, Zeitz et al. 2014). In this study, using
immunohistochemistry to assess EZH2 expression level, we found an increase expression of
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EZH2 in cancer than NA tissue (p=0.003), however, there was no difference of EZH2 between
DCIS tissue and invasive cancer tissue (p>0.05). We did not find any correlation between EZH2
and lncRNAs in either NA or DCIS tissue, however, we noticed only one strong correlation
(p=0.006) between EZH2 and KCNQ1OT1 in invasive tissue. Although whether H19 or
KCNQ1OT1 induce EZH2 is largely unknown, Chisholm’s paper showed HOTAIR and EZH2
are co-expressed in breast cancer. Because of our limited sample size, we might not be able to
confirm some correlations, but we still provided some evidence for co-expression of KCNQ1OT1
and EZH2 in invasive breast cancer.
Clinicopathological correlations
In the present study, by using Pearson correlation test and non-parametric ANOVA test, we found
HOTAIR positively trends trend with Her2 (p=0.013) and Ki67 (p=0.044), H19 positively
correlates with Ki67 (p=0.045) in DCIS. Interestingly, only one true correlation between
KCNQ1OT1 and clinicopathological factors, which was Ki67, was identified (p=0.043) although
our screening Pearson test proposed multiple associations, indicating Pearson test is not robust
when one variable is categorical. With invasive clinicopathological factors, only HOTAIR
significantly associates with Ki67 (p=0.019). However, by performing same test by using threetiered score of lncRNAs as a filter, we could find more robust associations, for example, in DCIS,
HOTAIR only significantly correlated with Her2 (p=0. 03) and H19 positively associates with
Ki67 (p=0.047); in invasive cancer, HOTAIR highly associates with Her2 (p=0.032) and Ki67
(p=0.039), KCNQ1OT1 positively correlates with Her2 (p=0.032) and negatively marginal
correlates with PR positivity (p=0.05) , providing more important insights for clinicopathological
correlations. By using univariate analysis on our dichotomous data, we were able to find a
significant positive association between HOTAIR and histological grade (p=0.011) with odds
ratio of 14.167. Our regression equation is

, indicating the odds is

5.668 if this subject has high expressed HOTAIR and odds is 0.4 if this case has low HOTAIR
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expression level. We subsequently converted odds to probabilities, resulting in a probability of
0.85 with predictor variable coded with 1, but a probability of 0.29 with predictor variable coded
with 0, indicating our model can predict 85% HOTAIR high expression (coded with 1) will have
non-low grade invasive breast cancer (coded with 1), while this model can predict only 29% cases
with higher HOTAIR expression will have non-low grade cancer, also suggesting HOTAIR is an
informative independent prognostic factor for invasive cancer aggressiveness. Previous studies
have already reported HOTAIR highly associated with primary tumor grade in colorectal cancer,
epithelia ovarian cancer and gastric cancer, and we confirm it in primary breast tumor (Kogo,
Shimamura et al. 2011; Emadi-Andani, Nikpour et al. 2014; Qiu, Lin et al. 2014). Subsequent
multivariate analysis suggested the combination of lymphovascular invasion and HOTAIR
expression was able to result in better prediction for histological grade with an odds ratio of 16.5.
Our equation is

, where X1 represents

lymphovascular invasion status and X2 represents HOTAIR. As we can notice that HOTAIR
positively relates with odds while LVI status had a negative relationship with odds in our model.
The odds is 11 when the case presents LVI negative while has highly expressed HOTAIR,
resulting in a probability of 0.92, which indicates our model predicts that 92% of cases with LVI
negative and high HOTAIR status will have a more aggressive cancer. However, the odds is 0.08
for cases that have both positive LVI and low HOTAIR expression. The probability is 0.07,
indicating that our model predicts only 7% of patients who have been found with low HOTAIR
and positive LVI, will eventually have a cancer beyond low histological grade. Although
currently standard H&E staining is an easy and informative approach for grading cancer,
HOTAIR also may be a useful adjunct test for the evaluation of equivocal grades. We also found
a few cases that deviated from the trend, i.e., low HOTAIR expression in high-grade tumors: this
type of dysregulation in invasive cancer might represent a specific subgroup of invasive cancers;
further HOTAIR studies are required. As all the comparisons in this study were tested between
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DCIS, invasive tissue and normal adjacent tissue, further studies are also required comparing
lncRNA expression in tumor tissues to lncRNA expression in normal tissues from healthy women.

RNAscope SpotStudioTM software
Manual scoring is time consuming and prone to subjectivity and poor reproducibility, however,
RNAscope SpotStudioTM software is an intuitive automated system that is designed specifically
for RNAscope technology for quantification. Generally, it quantifies signal intensity and area in
single molecule sensitivity. This present study also utilized this software package for HOTAIR
and KCNQ1OT1 as an adjunct quantification because their signal are mostly dots rather than
whole nucleus stain of MEG3 or “streak” stain around ducts boundary of H19. Significant
correlations between eye-scored lncRNA expression level and software-scored lncRNA
expression level were both found in HOTAIR and KCNQ1OT1 across different tissue types, with
an exception of HOTAIR in NA tissue. However, we found some inconsistent results when we
used software generated results for tissue comparison study and clinicopathological correlations
study, largely because there were a few extreme observations identified by SpotStudioTM that
increase too much variability. Although image analysis tool prone to provide standard
quantification, it also requires operator to manually select regions of interest, optimize nucleus
diameter and hematoxylin stain parameter that also might result in subjectivity. Moreover, strong
hematoxylin stain is very likely to perplex this image analysis system in recognition of true
signals. And more than that, too much variation has been observed in our limited samples so that
deviation increases remarkably in our statistical analysis, resulting in inconsistent consequences.
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Conclusion:
The primary goal of this research was to detect lncRNA molecules in FFPE specimens and test
for associations between lncRNA expression and clinicopathological factors. From our results,
we conclude that the RNAscope® CISH assay is a highly effective tool for visualizing lncRNA
expression. With this novel technology, we can not only quantify RNA expression to single copy
sensitivity, but also visualize RNA molecules and interpret their expression within the cellular
context, which is not possible by qPCR. Regarding the expression level of lncRNA across tissues,
we can conclude that oncogenic activity of HOTAIR, H19 and KCNQ1OT1 is demonstrated in
breast cancer by showing that all of them have significantly higher expression levels in cancer
tissue than normal adjacent. Also, both HOTAIR and H19 express significantly higher in invasive
cancer than non-invasive ductal carcinoma in situ. Moreover, some associations between lncRNA
and clinical items are suggested by the current investigation. HOTAIR was found to associate
with Her2 status in both DCIS and invasive cancer. HOTAIR was also concluded to be a critical
independent positive predictor for invasive cancer histological grade. The other two important
lncRNAs, KCNQ1OT1 and H19, were also found to correlate with some important clinical
factors. Although this study did not directly address the causal mechanisms by which lncRNA
aberrant expression relates to clinical status, it can be hypothesized on the basis of other
functional studies that lncRNAs participate in a spectrum of cell activities and that lncRNA
dysregulation promotes or attenuates tumor development. We also concluded that the use of
image analysis software facilitates standardized RNAscope data interpretation.

Project Summary and Future Direction

Both projects examined novel approaches for assessing biomarkers of breast carcinoma. The
perspectives are different: in the first study, we focused on tumor cell DNA content, which has
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previously been shown to have an association with breast cancer clinical and pathological
characteristics. Here, we developed an alternative technique for DNA content analysis by flow
cytometric analysis and show the utility of our novel tissue core sampling approach for measuring
DNA content in FFPE tissue specimens. Strikingly, we also found this alternative tissue sampling
method is a good approach for the intratumoral heterogeneity assay of solid breast tumors. Future
investigations would apply multiparametric approaches that combined DNA content, protein
markers labeling, and chromosomal changes to better identify distinct groups in breast carcinoma.
Moreover, future studies would be also able to utilize the proposed technique and single cell
sequencing to obtain a better understanding of the composition of tumors, and the significance for
prognosis and even personalized therapeutics.
In the second study, lncRNAs that may be biomarkers for both invasive breast cancer and DCIS
were examined by using RNAscope® CISH. We visualized and quantified lncRNA stains by
bright field microscopy. Several associations between lncRNAs and clinicopathlogical factors
have been found, suggesting potential utility of lncRNA CISH in breast carcinoma diagnostics.
Future studies require an increased sample size. A small sample size might cause too much
deviation that result in spurious correlations. With the help of the RNAscope CISH assay in
combination with TMAs, more and more lncRNAs probes can be designed and tested on either
preserved tissue of fresh tissue. Automated RNAscope CISH is also now possible supporting
high-throughput standardized research and clinical assays that can be combined with the
advanced semi-quantitative software supporting data analyses uncompromised by human
subjectivity. As we point out some associations already, functional studies would be another
direction to promote research of this discipline.
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